Reference(s)
Click here to return to the Reference Table

Descriptor: HGF/SF expression


Acute Myelogenous Leukemia

Reference Number: 181
Hino, M. et al. Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells. Br J Cancer 73, 119-23. (1996).
PubMed link      E-mail link

Reference Number: 182
Hjorth-Hansen, H. et al. Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia. Eur J Haematol 62, 129-34 (1999).
PubMed link      E-mail link

Reference Number: 183
Verstovsek, S. et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 15, 1165-70. (2001).
PubMed link      E-mail link

Adult T Cell Leukemia

Reference Number: 516
Choi YL, Tsukasaki K, O'Neill MC, Yamada Y, Onimaru Y, Matsumoto K, Ohashi J, Yamashita Y, Tsutsumi S, Kaneda R, Takada S, Aburatani H, Kamihira S, Nakamura T, Tomonaga M, Mano H. A genomic analysis of adult T-cell leukemia. Oncogene. 26, 1245-55 (2007)
PubMed link      E-mail link

Reference Number: 690
Onimaru Y, Tsukasaki K, Murata K, Imaizumi Y, Choi YL, Hasegawa H, Sugahara K, Yamada Y, Hayashi T, Nakashima M, Taguchi T, Mano H, Kamihira S, Tomonaga M. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met. Int J Oncol. 33, 697-703 (2008)
PubMed link      E-mail link

Bladder

Reference Number: 1
Joseph, A. et al. Expression of scatter factor in human bladder carcinoma. J Natl Cancer Inst 87, 372-7. (1995).
PubMed link      E-mail link

Reference Number: 2
Li, B., Kanamaru, H., Noriki, S., Fukuda, M. & Okada, K. Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Int J Urol 5, 436-40. (1998).
PubMed link      E-mail link

Reference Number: 549
Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle. 6, 1393-402 (2007)
PubMed link      E-mail link

Reference Number: 592
Wang P, Nishitani MA, Tanimoto S, Kishimoto T, Fukumori T, Takahashi M, Kanayama HO. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology. 69, 780-4 (2007)
PubMed link      E-mail link

Reference Number: 806
Eissa S, Swellam M, Labib RA, El-Zayat T, El Ahmady O. A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot. J Urol. 181, 1353-60 (2009)
PubMed link      E-mail link

Reference Number: 808
Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol. 40, 496-504 (2009)
PubMed link      E-mail link

Reference Number: 853
Bhuvaneswari R, Gan YY, Lucky SS, Chin WW, Ali SM, Soo KC, Olivo M. Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. Mol Cancer. 7, 56 (2008)
PubMed link      E-mail link

Reference Number: 1392
Hofner T1, Macher-Goeppinger S, Klein C, Rigo-Watermeier T, Eisen C, Pahernik S, Hohenfellner M, Trumpp A, Sprick MR. Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer. J Urol. 190, 2263-70 (2013)
PubMed link      E-mail link

Reference Number: 1511
Chiba S, Tsuchiya N, Horikawa Y, Narita S, Inoue T, Akihama S, Saito M, Numakura K, Tsuruta H, Huang M, Satoh S, Habuchi T. Functional mononucleotide repeat polymorphism in the promoter region of HGF is associated with risk and malignant aggressiveness of bladder cancer. Int J Oncol. 44, 678-84 (2014)
PubMed link      E-mail link

Reference Number: 1745
Grimm S, Jennek S, Singh R, Enkelmann A, Junker K, Rippaus N, Berndt A, Friedrich K. Malignancy of bladder cancer cells is enhanced by tumor-associated fibroblasts through a multifaceted cytokine-chemokine loop. Exp Cell Res. 335, 1-11 (2015)
PubMed link      E-mail link

Breast

Reference Number: 6
Edakuni, G., Sasatomi, E., Satoh, T., Tokunaga, O. & Miyazaki, K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 51, 172-8. (2001).
PubMed link      E-mail link

Reference Number: 7
Jin, L. et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 79, 749-60. (1997).
PubMed link      E-mail link

Reference Number: 8
Kang, J. Y. et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63, 1101-5 (2003).
PubMed link      E-mail link

Reference Number: 9
Nagy, J. et al. Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg Oncol 5, 15-21. (1996).
PubMed link      E-mail link

Reference Number: 10
Tuck, A. B., Park, M., Sterns, E. E., Boag, A. & Elliott, B. E. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 148, 225-32 (1996).
PubMed link      E-mail link

Reference Number: 11
Yamashita, J. et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54, 1630-3 (1994).
PubMed link      E-mail link

Reference Number: 12
Yao, Y. et al. Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. Am J Pathol 149, 1707-17 (1996).
PubMed link      E-mail link

Reference Number: 237
Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10:202-11 (2004).
PubMed link      E-mail link

Reference Number: 308
Coskun U, Bukan N, Sancak B, Gunel N, Ozenirler S, Unal A, Yucel A. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions. Neoplasma 51, 209-13 (2004)
PubMed link      E-mail link

Reference Number: 359
Matteucci E, Locati M, Desiderio MA. Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness. Exp Cell Res.  310 176-85 (2005)
PubMed link      E-mail link

Reference Number: 360
Sheen-Chen SM, Liu YW, Eng HL, Chou FF. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev. 14 715-7 (2005)
PubMed link      E-mail link

Reference Number: 404
Bigelow RL, Cardelli JA. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene. 25, 1922-30 (2006)
PubMed link      E-mail link

Reference Number: 528
Pruefer FG, Unger-Saldaña K, Mohamier L, Ramírez M, Suárez J, Ramirez MT, Maldonado V, Meléndez-Zajgla J. Tumor HGF lacks prognostic significance in Mexican breast cancer patients. J Exp Clin Cancer Res. 25, 357-64 (2006)
PubMed link      E-mail link

Reference Number: 532
Eichbaum MH, de Rossi TM, Kaul S, Bruckner T, Schneeweiss A, Sohn C. Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer. Tumour Biol. 28, 36-44 (2007)
PubMed link      E-mail link

Reference Number: 544
Matteucci E, Ridolfi E, Desiderio MA. Hepatocyte growth factor differently influences Met-E-cadherin phosphorylation and downstream signaling pathway in two models of breast cells. Cell Mol Life Sci. 63, 2016-26 (2006)
PubMed link      E-mail link

Reference Number: 547
Filigheddu N, Cutrupi S, Porporato PE, Riboni F, Baldanzi G, Chianale F, Fortina E, Piantanida P, De Bortoli M, Vacca G, Graziani A, Surico N. Diacylglycerol kinase is required for HGF-induced invasiveness and anchorage-independent growth of MDA-MB-231 breast cancer cells. Anticancer Res. 27, 1489-92 (2007)
PubMed link      E-mail link

Reference Number: 555
Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology. 51, 54-62 (2007)
PubMed link      E-mail link

Reference Number: 610
Lee WJ, Chen WK, Wang CJ, Lin WL, Tseng TH. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol. 226, 178-91 (2007)
PubMed link      E-mail link

Reference Number: 613
Sam MR, Elliott BE, Mueller CR. A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells. Mol Cancer. 6, 69 (2007)
PubMed link      E-mail link

Reference Number: 636
Leibowitz-Amit R, Tsarfaty G, Abargil Y, Yerushalmi GM, Horev J, Tsarfaty I. Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scattering and tumorigenicity by altering Met-HGF/SF signaling pathways. Cancer Res. 66, 8687-97 (2006)
PubMed link      E-mail link

Reference Number: 643
Xu H, Washington S, Verderame MF, Manni A. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells. Breast Cancer Res Treat. 112, 255-61 (2008)
PubMed link      E-mail link

Reference Number: 674
Takahashi K, Suzuki K. Requirement of kinesin-mediated membrane transport of WAVE2 along microtubules for lamellipodia formation promoted by hepatocyte growth factor. Exp Cell Res. 314, 2313-22 (2008)
PubMed link      E-mail link

Reference Number: 675
Yin YL, Chen HL, Kuo HM, He SP. NK3 and NK4 of HGF enhance filamin production via STAT pathway, but not NK1 and NK2 in human breast cancer cells. Acta Pharmacol Sin. 29, 728-35 (2008)
PubMed link      E-mail link

Reference Number: 676
Syed DN, Afaq F, Sarfaraz S, Khan N, Kedlaya R, Setaluri V, Mukhtar H. Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. Toxicol Appl Pharmacol. 231, 52-60 (2008)
PubMed link      E-mail link

Reference Number: 687
Wright TG, Singh VK, Li JJ, Foley JH, Miller F, Jia Z, Elliott BE. Increased production and secretion of HGF alpha-chain and an antagonistic HGF fragment in a human breast cancer progression model. Int J Cancer. 125, 1004-15 (2009)
PubMed link      E-mail link

Reference Number: 697
Ridolfi E, Matteucci E, Maroni P, Desiderio MA. Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs. Br J Cancer. 99, 1623-34. Epub 2008 Oct 21 (2008)
PubMed link      E-mail link

Reference Number: 839
Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P, Desiderio MA. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer. 46, 1679-91 (2010)
PubMed link      E-mail link

Reference Number: 848
Jedeszko C, Victor BC, Podgorski I, Sloane BF. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res. 69, 9148-55 (2009)
PubMed link      E-mail link

Reference Number: 955
Tyan SW, Kuo WH, Huang CK, Pan CC, Shew JY, Chang KJ, Lee EY, Lee WH. Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS One. 6, (e)15313 (2011)
PubMed link      E-mail link

Reference Number: 987
Ma J, DeFrances MC, Zou C, Johnson C, Ferrell R, Zarnegar R. Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J Clin Invest. 119, 478-91 (2009)
PubMed link      E-mail link

Reference Number: 1005
El-Attar HA, Ragab MS, Sheta MI, Ahmed AS. Hepatocyte growth factor in Egyptian females with breast benign lumps and cancers. Asian Pac J Cancer Prev. 11, 893-6 (2010)
PubMed link      E-mail link

Reference Number: 1066
Kucera R, Cerna M, Narsanska A, Svobodova S, Strakova M, Vrzalova J, Fuchsova R, Treskova I, Kydlicek T, Treska V, Pecen L, Topolcan O, Pazdiora P. Growth factors and breast tumors, comparison of selected growth factors with traditional tumor markers. Anticancer Res. 31, 4653-6 (2011)
PubMed link      E-mail link

Reference Number: 1154
Kim EJ, Eom SJ, Hong JE, Lee JY, Choi MS, Park JH. Benzyl isothiocyanate inhibits basal and hepatocyte growth factor-stimulated migration of breast cancer cells. Mol Cell Biochem. 359, 431-40 (2012)
PubMed link      E-mail link

Reference Number: 1199
Ahmed HH, Metwally FM, Mahdy ES, Shosha WG, Ramadan SS. Clinical value of serum hepatocyte growth factor, B-cell lymphoma-2 and nitric oxide in primary breast cancer patients. Eur Rev Med Pharmacol Sci. 16, 958-65 (2012)
PubMed link      E-mail link

Reference Number: 1200
Huang FI, Chen YL, Chang CN, Yuan RH, Jeng YM. Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion. Carcinogenesis. 33, 1142-8 (2012)
PubMed link      E-mail link

Reference Number: 1427
Harrison SM, Knifley T, Chen M, O'Connor KL1. LPA, HGF, and EGF utilize distinct combinations of signaling pathways to promote migration and invasion of MDA-MB-231 breast carcinoma cells. BMC Cancer. 13, 501 (2013)
PubMed link      E-mail link

Reference Number: 1451
Sundaram S1, Freemerman AJ, Johnson AR, Milner JJ, McNaughton KK, Galanko JA, Bendt KM, Darr DB, Perou CM, Troester MA, Makowski L. Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer. Breast Cancer Res Treat. 142, 489-503 (2013)
PubMed link      E-mail link

Reference Number: 1541
Chen P, Mo Q, Wang B, Weng D, Wu P, Chen G. Breast cancer associated fibroblasts promote MCF-7 invasion in vitro by secretion of HGF. J Huazhong Univ Sci Technolog Med Sci. 32, 92-6 (2012)
PubMed link      E-mail link

Reference Number: 1542
Casbas-Hernandez P, D'Arcy M, Roman-Perez E, Brauer HA, McNaughton K, Miller SM, Chhetri RK, Oldenburg AL, Fleming JM, Amos KD, Makowski L, Troester MA. Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. Breast Cancer Res. 15, R82 (2013)
PubMed link      E-mail link

Reference Number: 1600
Lee YH, Morrison BL, Bottaro DP. Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J Biol Chem. 289, 20448-61 (2014)
PubMed link      E-mail link

Reference Number: 1683
Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res. 14, R104 (2012)
PubMed link      E-mail link

Reference Number: 1733
Yang H, Zhang C, Cui S Expression of hepatocyte growth factor in breast cancer and its effect on prognosis and sensitivity to chemotherapy. Mol Med Rep. 11, 1037-42 (2015)
PubMed link      E-mail link

Reference Number: 1860
Bendinelli P, Maroni P, Matteucci E, Desiderio MA. HGF and TGFß1 differently influenced Wwox regulatory function on Twist program for mesenchymal-epithelial transition in bone metastatic versus parental breast carcinoma cells. Mol Cancer. 14, 112 (2015)
PubMed link      E-mail link

Cervical

Reference Number: 239
Walker F, Kermorgant S, Darai E, Madelenat P, Cremieux AC, Henin D, Lehy T. Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus. Clin Cancer Res 9:273-84 (2003).
PubMed link      E-mail link

Reference Number: 398
Tsai HW, Chow NH, Lin CP, Chan SH, Chou CY, Ho CL. The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma. Hum Pathol. 37, 198-204. Epub 2005 Dec 20 (2006)
PubMed link      E-mail link

Reference Number: 467
Majka M, Drukala J, Lesko E, Wysoczynski M, Jenson AB, Ratajczak MZ. SDF-1 alone and in co-operation with HGF regulates biology of human cervical carcinoma cells. Folia Histochem Cytobiol. 44, 44155-64 (2006)
PubMed link      E-mail link

Reference Number: 1232
Horn LC, Hommel N, Roschlau U, Bilek K, Hentschel B, Einenkel J. Peritumoral stromal remodeling, pattern of invasion and expression of c-met/HGF in advanced squamous cell carcinoma of the cervix uteri, FIGO stages III and IV. Eur J Obstet Gynecol Reprod Biol. 163, 76-80 (2012)
PubMed link      E-mail link

Reference Number: 1592
Zhang Y, Wu JZ, Yang YQ, Ma R, Zhang JY, Feng JF Expression of growth regulated oncogene 1, hepatocyte growth factor, platelet derived growth factor AA and soluble E selectin and their association with high risk human papillomavirus infection in squamous cell carcinoma of the uterine cervix. Mol Med Rep. 10, 1013-24 (2014)
PubMed link      E-mail link

Cholangiocarcinoma

Reference Number: 470
Leelawat K, Leelawat S, Tepaksorn P, Rattanasinganchan P, Leungchaweng A, Tohtong R, Sobhon P. Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. J Surg Res. 136, 78-84 (2006)
PubMed link      E-mail link

Reference Number: 850
Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber-Gunckel M, Lippert E, Klebl F, Rogler G. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer. 10, 302 (2010)
PubMed link      E-mail link

Reference Number: 851
Menakongka A, Suthiphongchai T. Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol. 16, 713-22 (2010)
PubMed link      E-mail link

Reference Number: 852
Piscaglia AC, Shupe TD, Pani G, Tesori V, Gasbarrini A, Petersen BE. Establishment of cancer cell lines from rat hepatocholangiocarcinoma and assessment of the role of granulocyte-colony stimulating factor and hepatocyte growth factor in their growth, motility and survival. J Hepatol. 51, 77-92 (2009)
PubMed link      E-mail link

Reference Number: 1405
Ge X1, Wang Y, Li Q, Yu H, Ji G, Miao L. NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. Oncol Rep. 30, 448-54 (2013)
PubMed link      E-mail link

Chronic Myeloid Leukemia

Reference Number: 181
Hino, M. et al. Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells. Br J Cancer 73, 119-23. (1996).
PubMed link      E-mail link

Reference Number: 273
Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, Chae SC, Lee KS, Lee KB. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma. 46, 885-91 (2005)
PubMed link      E-mail link

Reference Number: 849
Zhelyazkova AG, Tonchev AB, Kolova P, Ivanova L, Gercheva L. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia. Scand J Clin Lab Invest. 68, 492-500 (2008)
PubMed link      E-mail link

Reference Number: 1208
Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 18, 1118-22 (2012)
PubMed link      E-mail link

Reference Number: 1276
Cerny-Reiterer S, Ghanim V, Hoermann G, Aichberger KJ, Herrmann H, Muellauer L, Repa A, Sillaber C, Walls AF, Mayerhofer M, Valent P. Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression. Neoplasia. 14, 572-84 (2012)
PubMed link      E-mail link

Colorectal

Reference Number: 31
Fukuura, T., Miki, C., Inoue, T., Matsumoto, K. & Suzuki, H. Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. Br J Cancer 78, 454-9. (1998).
PubMed link      E-mail link

Reference Number: 32
Otte, J. M. et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 61, 237-46 (2000).
PubMed link      E-mail link

Reference Number: 362
Yoshimura M, Fujiwara H, Kubota T, Amaike H, Takashima K, Inada S, Atsuji K, Araki Y, Matsumoto K, Nakamura T, Yamagishi H. Possible inhibition of cancer cell adhesion to the extracellular matrix in NK4-induced suppression of peritoneal implantation. Anticancer Res. 25, 3847-54 (2005) Erratum in: Anticancer Res. 26, 445 (2006)
PubMed link      E-mail link

Reference Number: 363
Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, Sturzebecher J, Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol. 27, 1061-70 (2005)
PubMed link      E-mail link

Reference Number: 437
Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakansson L, Groenewegen G, Lawrance J, Tang M, Wauk L, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer (EORTC). Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer.  41, 555-63(2005)
PubMed link      E-mail link

Reference Number: 479
Rasola A, Fassetta M, De Bacco F, D'Alessandro L, Gramaglia D, Di Renzo MF, Comoglio PM. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene. 26, 1078-87 (2007)
PubMed link      E-mail link

Reference Number: 480
Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248, 219-28 (2007)
PubMed link      E-mail link

Reference Number: 481
Jie JZ, Wang JW, Qu JG, Wang W, Hung T. Effects of adenoviral-mediated gene transduction of NK4 on proliferation, movement, and invasion of human colonic LS174T cancer cells in vitro. World J Gastroenterol. 12, 3983-8 (2006)
PubMed link      E-mail link

Reference Number: 482
Fassetta M, D'Alessandro L, Coltella N, Di Renzo MF, Rasola A. Hepatocyte growth factor installs a survival platform for colorectal cancer cell invasive growth and overcomes p38 MAPK-mediated apoptosis. Cell Signal. 18, 1967-76 (2006)
PubMed link      E-mail link

Reference Number: 485
Inoue Y, Miki C, Watanabe H, Ojima E, Kusunoki M. Genomic instability and tissue expression of angiogenic growth factors in sporadic colorectal cancer. Surgery. 139, 305-11 (2006)
PubMed link      E-mail link

Reference Number: 564
Zhang YH, Wei W, Xu H, Wang YY, Wu WX. Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways. Chin Med J (Engl). 120, 743-8 (2007)
PubMed link      E-mail link

Reference Number: 590
Baldus SE, Kort EJ, Schirmacher P, Dienes HP, Resau JH. Quantification of MET and hepatocyte growth factor/scatter factor expression in colorectal adenomas, carcinomas and non-neoplastic epithelia by quantitative laser scanning microscopy. Int J Oncol. 31, 199-204 (2007)
PubMed link      E-mail link

Reference Number: 837
Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K, Yoshida K. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer. Hepatogastroenterology. 57, 76-80 (2010)
PubMed link      E-mail link

Reference Number: 855
Paduch R, Jakubowicz-Gil J, Niedziela P. Hepatocyte growth factor (HGF), heat shock proteins (HSPs) and multidrug resistance protein (MRP) expression in co-culture of colon tumor spheroids with normal cells after incubation with interleukin-1beta (IL-1beta) and/or camptothecin (CPT-11). Indian J Exp Biol. 48, 354-64 (2010)
PubMed link      E-mail link

Reference Number: 875
Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K, Kusunoki M. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer. 125, 1657-62 (2009)
PubMed link      E-mail link

Reference Number: 876
Moore AE, Greenhough A, Roberts HR, Hicks DJ, Patsos HA, Williams AC, Paraskeva C. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis. 30, 1796-804 (2009)
PubMed link      E-mail link

Reference Number: 1062
Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Fujikawa H, Matsushita K, Okugawa Y, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy. Int J Oncol. 40, 583-91 (2012)
PubMed link      E-mail link

Reference Number: 1063
Kumara HM, Tohme ST, Kim IY, Kim DG, Kalady MF, Luchtefeld M, Hoffman K, Dimaggio V, Whelan RL. Minimally invasive colorectal resection is associated with a transient increase in plasma hepatocyte growth factor levels early after surgery for colon cancer. Surg Innov. 18, 254-8 (2011)
PubMed link      E-mail link

Reference Number: 1201
Tian M, Yu L, Zhang Y, Gao X. Correlations between SUVmax and expression of GLUT1 and growth factors inducing lymphangiogenesis. Acad Radiol. 19, 420-6 (2012)
PubMed link      E-mail link

Reference Number: 1345
Sun YL1, Liu WD, Ma GY, Gao DW, Jiang YZ, Liu Q, Du JJ. Expression of HGF and Met in human tissues of colorectal cancers: biological and clinical implications for synchronous liver metastasis. Int J Med Sci. 10, 548-59 (2013)
PubMed link      E-mail link

Reference Number: 1387
Tanahashi T1, Osada S, Yamada A, Kato J, Yawata K, Mori R, Imai H, Sasaki Y, Saito S, Tanaka Y, Nonaka K, Yoshida K. Extracellular signal-regulated kinase and Akt activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition. Int J Oncol. 42, 556-64 (2013)
PubMed link      E-mail link

Reference Number: 1389
Matsumura A1, Kubota T, Taiyoh H, Fujiwara H, Okamoto K, Ichikawa D, Shiozaki A, Komatsu S, Nakanishi M, Kuriu Y, Murayama Y, Ikoma H, Ochiai T, Kokuba Y, Nakamura T, Matsumoto K, Otsuji E. HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. Int J Oncol. 42, 535-42 (2013)
PubMed link      E-mail link

Reference Number: 1447
Takahashi N1, Yamada Y1, Furuta K2, Honma Y1, Iwasa S1, Takashima A1, Kato K1, Hamaguchi T1, Shimada Y1. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer. 110, 2716-27 (2014)
PubMed link      E-mail link

Reference Number: 1494
Swietlicki EA, Bala S, Lu J, Shaker A, Kularatna G, Levin MS, Rubin DC. Epimorphin deletion inhibits polyposis in the Apcmin/ mouse model of colon carcinogenesis via decreased myofibroblast HGF secretion. Am J Physiol Gastrointest Liver Physiol. 305, G564-72 (2013)
PubMed link      E-mail link

Reference Number: 1588
Seneviratne D, Ma J, Tan X, Kwon YK, Muhammad E, Melhem M, DeFrances MC, Zarnegar R Genomic instability causes HGF gene activation in colon cancer cells, promoting their resistance to necroptosis. Gastroenterology. 48, 181-191.e17 (2015)
PubMed link      E-mail link

Reference Number: 1709
Yonesaka K, Satoh T, Ueda S, Yoshida T, Takeda M, Shimizu T, Okamoto I, Nishio K, Tamura T, Nakagawa K Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. Anticancer Res. 35, 1683-9 (2015)
PubMed link      E-mail link

Reference Number: 1734
Bigatto V, De Bacco F, Casanova E, Reato G, Lanzetti L, Isella C, Sarotto I, Comoglio PM, Boccaccio C TNF-a promotes invasive growth through the MET signaling pathway. Mol Oncol. 9, 377-88 (2015)
PubMed link      E-mail link

Reference Number: 1759
Hinz S, Tepel J, Röder C, Kalthoff H, Becker T. Profile of serum factors and disseminated tumor cells before and after radiofrequency ablation compared to resection of colorectal liver metastases - a pilot study. Anticancer Res. 35, 2961-7 (2015)
PubMed link      E-mail link

Reference Number: 1760
Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. Cancer Sci. 106, 604-10 (2015)
PubMed link      E-mail link

Reference Number: 1824
Li F, Zhu YT. HGF-activated colonic fibroblasts mediates carcinogenesis of colonic epithelial cancer cells via PKC-cMET-ERK1/2-COX-2 signaling. Cell Signal. 27, 860-6 (2015)
PubMed link      E-mail link

Endometrial

Reference Number: 577
Yoshida S, Harada T, Iwabe T, Taniguchi F, Fujii A, Sakamoto Y, Yamauchi N, Shiota G, Terakawa N. Induction of hepatocyte growth factor in stromal cells by tumor-derived basic fibroblast growth factor enhances growth and invasion of endometrial cancer. J Clin Endocrinol Metab. 87, 2376-83 (2002)
PubMed link      E-mail link

Reference Number: 578
Wagatsuma S, Konno R, Sato S, Yajima A. Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer. 82, 520-30 (1998)
PubMed link      E-mail link

Reference Number: 580
Bae-Jump V, Segreti EM, Vandermolen D, Kauma S. Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro. Gynecol Oncol. 73, 265-72 (1999)
PubMed link      E-mail link

Reference Number: 831
Choi DS, Kim HJ, Yoon JH, Yoo SC, Jo H, Lee SY, Min CK, Ryu HS. Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-alpha and stromal derived hepatocyte growth factor. Int J Cancer. 124, 2528-38 (2009)
PubMed link      E-mail link

Reference Number: 1114
Yoshizawa Y, Yamada Y, Kanayama S, Shigetomi H, Kawaguchi R, Yoshida S, Nagai A, Furukawa N, Oi H, Kobayashi H. Signaling pathway involved in cyclooxygenase-2 up-regulation by hepatocyte growth factor in endometrial cancer cells. Oncol Rep. 26, 957-64 (2011)
PubMed link      E-mail link

Reference Number: 1772
Li M, Xin X, Wu T, Hua T, Wang H, Wang H. Stromal cells of endometrial carcinoma promotes proliferation of epithelial cells through the HGF/c-Met/Akt signaling pathway. Tumour Biol. 36, 6239-48 (2015)
PubMed link      E-mail link

Reference Number: 1870
Nakamura M, Ono YJ, Kanemura M, Tanaka T, Hayashi M, Terai Y, Ohmichi M. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum. Gynecol Oncol. 139, 345-54 (2015)
PubMed link      E-mail link

Esophogeal

Reference Number: 397
Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang AC, Chambers AF, Giordano TJ, Glover TW, Beer DG. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene. 25, 409-18 (2006)
PubMed link      E-mail link

Reference Number: 443
Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung L, Chen Y, Huang X, Chan HM, Zhao P, Luk J, Vande Woude G, Wong J. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res. 11, 6190-7 (2005)
PubMed link      E-mail link

Reference Number: 486
Watson GA, Zhang X, Stang MT, Levy RM, Queiroz de Oliveira PE, Gooding WE, Christensen JG, Hughes SJ. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia. 8, 949-55 (2006)
PubMed link      E-mail link

Reference Number: 487
Anderson MR, Harrison R, Atherfold PA, Campbell MJ, Darnton SJ, Obszynska J, Jankowski JA. Met receptor signaling: a key effector in esophageal adenocarcinoma. Clin Cancer Res. 12, 5936-43 (2006)
PubMed link      E-mail link

Reference Number: 832
Grugan KD, Miller CG, Yao Y, Michaylira CZ, Ohashi S, Klein-Szanto AJ, Diehl JA, Herlyn M, Han M, Nakagawa H, Rustgi AK. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc Natl Acad Sci U S A. 107, 11026-31 (2010)
PubMed link      E-mail link

Gastric

Reference Number: 41
Wu, C. W. et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 5, 817-22. (1998).
PubMed link      E-mail link

Reference Number: 314
Suzuki M, Suzuki H, Masaoka T, Tanaka S, Suzuki K, Ishii H. Helicobacter pylori eradication treatment modulates epithelial cell proliferation and tissue content of hepatocyte growth factor in the gastric mucosa. Aliment Pharmacol Ther 20, 158-64 (2004)
PubMed link      E-mail link

Reference Number: 491
Lee KH, Choi EY, Kim MK, Hyun MS, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, Kim JR. Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines. Exp Mol Med. 38, 27-35 (2006)
PubMed link      E-mail link

Reference Number: 893
Lee KH, Choi EY, Kim MK, Hyun MS, Eun JR, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, Kim JR. Hepatocyte growth factor promotes cell survival by phosphorylation of BAD in gastric cancer cells. Oncol Res. 17, 23-32 (2008)
PubMed link      E-mail link

Reference Number: 894
Zhang W, Chu YQ, Ye ZY, Zhao ZS, Tao HQ. Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer. Anat Rec (Hoboken). 292, 1114-21 (2009)
PubMed link      E-mail link

Reference Number: 895
Lee KH, Kim SW, Kim JR. Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth factor in stomach cancer cells. J Exp Clin Cancer Res. 28, 73 (2009)
PubMed link      E-mail link

Reference Number: 896
Li C, Ma Y, Xue Y, Zhang H, Wei Y. Molecular characterization and significance for prognosis of free gastric cancer cells in the peritoneal cavity. Hepatogastroenterology. 56, 891-8 (2009)
PubMed link      E-mail link

Reference Number: 928
Lee KH, Choi EY, Kim MK, Lee SH, Jang BI, Kim TN, Kim SW, Kim SW, Song SK, Kim JR, Jung BC. Hepatoma-derived growth factor regulates the bad-mediated apoptotic pathway and induction of vascular endothelial growth factor in stomach cancer cells. Oncol Res. 19, 67-76 (2010)
PubMed link      E-mail link

Reference Number: 1145
Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K, Mohri Y, Inoue Y, Goel A, Kusunoki M. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer. 130, 2912-21 (2012)
PubMed link      E-mail link

Reference Number: 1218
Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, Xu JB, Zan WH. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 106, 304-10 (2012)
PubMed link      E-mail link

Reference Number: 1297
Wu X, Chen X, Zhou Q, Li P, Yu B, Li J, Qu Y, Yan J, Yu Y, Yan M, Zhu Z, Liu B, Su L. Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer. Cancer Lett. 335, 128-35 (2013)
PubMed link      E-mail link

Reference Number: 1319
Mohri Y, Miki C, Tanaka K, Kawamoto A, Ohi M, Yokoe T, Kusunoki M. Clinical correlations and prognostic relevance of tissue angiogenic factors in patients with gastric cancer. Clin Oncol (R Coll Radiol). 24, 610-6 (2012)
PubMed link      E-mail link

Reference Number: 1458
Zhao L, Yasumoto K, Kawashima A, Nakagawa T, Takeuchi S, Yamada T, Matsumoto K, Yonekura K, Yoshie O, Yano S. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. Cancer Sci. 104, 1640-6 (2013)
PubMed link      E-mail link

Reference Number: 1612
Lee KH, Choi EY, Koh SA, Kim MK, Jang BI, Kim SW, Kim JR. IL-1ß-stimulated urokinase plasminogen activator expression through NF-?B in gastric cancer after HGF treatment. Oncol Rep. 31, 2123-30 (2014)
PubMed link      E-mail link

Reference Number: 1625
Koh SA, Kim MK, Lee KH, Kim SW, Kim JR. RhoGDI2 is associated with HGF-mediated tumor invasion through VEGF in stomach cancer. Clin Exp Metastasis. 31, 805-15 (2014)
PubMed link      E-mail link

Reference Number: 1691
Hao NB, Tang B, Wang GZ, Xie R, Hu CJ, Wang SM, Wu YY, Liu E, Xie X, Yang SM. Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-?B signaling pathway for gastric cancer metastasis. Cancer Lett.361, 57-66 (2015)
PubMed link      E-mail link

Reference Number: 1813
Noguchi E, Saito N, Kobayashi M, Kameoka S. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep. 11, 3423-31 (2015)
PubMed link      E-mail link

Glioblastomas/Astrocytomas

Reference Number: 185
Arrieta, O. et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 94, 3210-8 (2002).
PubMed link      E-mail link

Reference Number: 186
Koochekpour, S. et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57, 5391-8 (1997).
PubMed link      E-mail link

Reference Number: 187
Kunkel, P. et al. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro-oncol 3, 82-8 (2001).
PubMed link      E-mail link

Reference Number: 188
Lamszus, K., Laterra, J., Westphal, M. & Rosen, E. M. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 17, 517-30 (1999).
PubMed link      E-mail link

Reference Number: 189
Moriyama, T., Kataoka, H., Koono, M. & Wakisaka, S. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review). Int J Mol Med 3, 531-6 (1999).
PubMed link      E-mail link

Reference Number: 517
Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 12, 6144-52 (2006)
PubMed link      E-mail link

Reference Number: 519
Ma Y, Yuan RQ, Fan S, Hu C, Goldberg ID, Laterra JJ, Rosen EM. Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum. Anticancer Drugs. 17, 733-51 (2006)
PubMed link      E-mail link

Reference Number: 568
Chu SH, Ma YB, Zhang H, Feng DF, Zhu ZA, Li ZQ, Yuan XH. Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells. J Neurooncol. 85, 33-8 (2007)
PubMed link      E-mail link

Reference Number: 607
Jun HT, Sun J, Rex K, Radinsky R, Kendall R, Coxon A, Burgess TL. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 13, 6735-42 (2007)
PubMed link      E-mail link

Reference Number: 623
Sheng-Hua C, Yan-Bin M, Zhi-An Z, Hong Z, Dong-Fu F, Zhi-Qiang L, Xian-Hou Y. Radiation-enhanced hepatocyte growth factor secretion in malignant glioma cell lines. Surg Neurol. 68, 610-3 (2007)
PubMed link      E-mail link

Reference Number: 666
Wondergem R, Ecay TW, Mahieu F, Owsianik G, Nilius B. HGF/SF and menthol increase human glioblastoma cell calcium and migration. Biochem Biophys Res Commun. 372, 210-5 (2008)
PubMed link      E-mail link

Reference Number: 719
Binning MJ, Niazi T, Pedone CA, Lal B, Eberhart CG, Kim KJ, Laterra J, Fults DW. Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth. Cancer Res. 68, 7838-45 (2008)
PubMed link      E-mail link

Reference Number: 864
Garcia-Navarrete R, Garcia E, Arrieta O, Sotelo J. Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. J Neurooncol. 97, 347-51 (2010)
PubMed link      E-mail link

Reference Number: 1016
Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A. 98, 7443-8 (2001)
PubMed link      E-mail link

Reference Number: 1060
Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, Essenburg C, Kaufman DW, DeKoning T, Enter MA, O'Rourke TJ, Marincola FM, Vande Woude GF. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A. 109, 570-5 (2012)
PubMed link      E-mail link

Reference Number: 1358
Garnett J1, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K, Yao J, Priebe W, Colman H, Elferink LA, Bogler O. Regulation of HGF expression by ?EGFR-mediated c-Met activation in glioblastoma cells. Neoplasia. 15, 73-84 (2013)
PubMed link      E-mail link

Reference Number: 1423
Murray DW1, Didier S2, Chan A2, Paulino V3, Van Aelst L4, Ruggieri R2, Tran NL3, Byrne AT5, Symons M2. Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation. Br J Cancer. 110, 1307-15 (2014)
PubMed link      E-mail link

Reference Number: 1627
Feng C, Cao S. Activation of STAT5 contributes to proliferation in U87 human glioblastoma multiforme cells. Mol Med Rep. 10, 203-10 (2014)
PubMed link      E-mail link

Head and Neck

Reference Number: 50
Marshall, D. D. & Kornberg, L. J. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 108, 1413-7 (1998).
PubMed link      E-mail link

Reference Number: 51
Uchida, D. et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 93, 489-96 (2001).
PubMed link      E-mail link

Reference Number: 259
Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 9:68-75 (2003).
PubMed link      E-mail link

Reference Number: 399
Aoki T, Tsukinoki K, Kurabayashi H, Sasaki M, Yasuda M, Ota Y, Watanabe Y, Kaneko A. Hepatocyte growth factor expression correlates with cyclooxygenase-2 pathway in human salivary gland tumors. Oral Oncol. 42, 51-6 (2006)
PubMed link      E-mail link

Reference Number: 406
Druzgal CH, Chen Z, Yeh NT, Thomas GR, Ondrey FG, Duffey DC, Vilela RJ, Ende K, McCullagh L, Rudy SF, Muir C, Herscher LL, Morris JC, Albert PS, Van Waes C. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck27, 771-84 (2005)
PubMed link      E-mail link

Reference Number: 484
Kim CH, Moon SK, Bae JH, Lee JH, Han JH, Kim K, Choi EC. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol. 126, 88-94 (2006)
PubMed link      E-mail link

Reference Number: 629
Kim CH, Lee JS, Kang SO, Bae JH, Hong SP, Kahng H. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncol. 43, 1021-5 (2007)
PubMed link      E-mail link

Reference Number: 639
Kim CH, Kim J, Kahng H, Choi EC. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma. Ann Surg Oncol. 14, 1565-74 (2007)
PubMed link      E-mail link

Reference Number: 655
Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 15, 3740-50 (2009)
PubMed link      E-mail link

Reference Number: 668
Hara S, Nakashiro K, Goda H, Hamakawa H. Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. Biochem Biophys Res Commun. 370, 123-8 (2008)
PubMed link      E-mail link

Reference Number: 801
Xie LQ, Bian LJ, Li Z, Li Y, Li ZX, Li B. Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol. 17, 1927-36 (2010)
PubMed link      E-mail link

Reference Number: 926
Scianna M, Merks RM, Preziosi L, Medico E. Individual cell-based models of cell scatter of ARO and MLP-29 cells in response to hepatocyte growth factor. J Theor Biol. 260, 151-60 (2009)
PubMed link      E-mail link

Reference Number: 968
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021-31 (2009)
PubMed link      E-mail link

Reference Number: 1037
Susuki D, Kimura S, Naganuma S, Tsuchiyama K, Tanaka T, Kitamura N, Fujieda S, Itoh H. Regulation of microRNA expression by hepatocyte growth factor in human head and neck squamous cell carcinoma. Cancer Sci. 102, 2164-71 (2011)
PubMed link      E-mail link

Reference Number: 1144
Le QT, Fisher R, Oliner KS, Young RJ, Cao H, Kong C, Graves E, Hicks RJ, McArthur GA, Peters L, O'Sullivan B, Giaccia A, Rischin D. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res. 18, 1798-807 (2012)
PubMed link      E-mail link

Reference Number: 1287
Singleton KR, Kim J, Hinz TK, Marek LA, Casás-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol Pharmacol. 83, 882-93 (2013)
PubMed link      E-mail link

Reference Number: 1611
Koo BS, Kim JM, Seo ST, Yoon YH, Kwon KR, Kim SH, Kwon HW, Bae WJ, Lim YC. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol. 21, 2310-7 (2014)
PubMed link      E-mail link

Kaposi's Sarcoma

Reference Number: 156
Maier JA, Mariotti M, Albini A, Comi P, Prat M, Comogilio PM, Soria MR. Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. Int J Cancer. 65, 168-72 (1996)
PubMed link      E-mail link

Reference Number: 157
Polverini, P. J. & Nickoloff, B. J. Role of scatter factor and the c-met protooncogene in the pathogenesis of AIDS-associated Kaposi's sarcoma. Adv Cancer Res 66, 235-53 (1995).
PubMed link      E-mail link

Reference Number: 158
Puig, L. et al. Differential expression of c-Met in Kaposi's sarcoma according to progression stage and HIV infection status. J Cutan Pathol 26, 227-31 (1999).
PubMed link      E-mail link

Reference Number: 407
Bardelli C, Sala M, Cavallazzi U, Prat M. Agonist Met antibodies define the signalling threshold required for a full mitogenic and invasive program of Kaposi's Sarcoma cells. Biochem Biophys Res Commun. 334, 1172-9 (2005)
PubMed link      E-mail link

Reference Number: 408
Montaldo F, Maffe A, Morini M, Noonan D, Giordano S, Albini A, Prat M. Expression of functional tyrosine kinases on immortalized Kaposi's sarcoma cells. J Cell Physiol.  184, 246-54 (2000)
PubMed link      E-mail link

Reference Number: 409
Maier J, Mariotti M, Comoglio PM, Soria MR. Interleukin 1 induces an autocrine loop hepatocyte growth factor/c-Met in murine Kaposi-like spindle cells. Oncogene. 13, 1009-15 (1996)

PubMed link      E-mail link

Reference Number: 494
Puig L, Fernández-Figueras MT, Penín RM, Esquius M, Alomar A, Ariza A. Differential expression of c-Met in Kaposi's sarcoma according to progression stage and HIV infection status. J Cutan Pathol. 26, 227-31 (1999)
PubMed link      E-mail link

Kidney

Reference Number: 60
Oh, R. R. et al. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas. Apmis 110, 229-38 (2002).
PubMed link      E-mail link

Reference Number: 286
Konda R, Sato H, Hatafuku F, Nozawa T, Ioritani N, Fujioka T. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. J Urol 171, 2166-70 (2004)
PubMed link      E-mail link

Reference Number: 490
Peruzzi B, Athauda G, Bottaro DP. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci U S A. 103, 14531-6 (2006)
PubMed link      E-mail link

Reference Number: 529
Peruzzi B, Bottaro DP. Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease. Cell Cycle. 5, 2839-41 (2006)
PubMed link      E-mail link

Reference Number: 539
Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y, Kataoka H. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 98, 491-8 (2007)
PubMed link      E-mail link

Reference Number: 670
Tanimoto S, Fukumori T, El-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, Nakanishi R, Yamamoto Y, Taue R, Yamaguchi K, Nakatsuji H, Kishimoto T, Izaki H, Oka N, Takahashi M, Kanayama HO. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest. 55, 106-11 (2008)
PubMed link      E-mail link

Reference Number: 732
Vuononvirta R, Sebire NJ, Messahel B, Perusinghe N, Reis-Filho JS, Pritchard-Jones K, Vujanic GM, Jones C. Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development. Clin Cancer Res. 15, 2723-30 (2009)
PubMed link      E-mail link

Reference Number: 833
Xie LQ, Bian LJ, Li Z, Li Y, Liang YJ. Co-elevated expression of hepatocyte growth factor and Interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma. Oncol Rep. 23, 141-50 (2010)
PubMed link      E-mail link

Reference Number: 1120
Vidyashankar S, Varma SR, Azeemudin M, Godavarthi A, Krishna NS, Patki PS. A novel herbal formulation "LiverCare" differentially regulates primary rat hepatocyte and hepatocarcinoma cell proliferation in vitro. J Med Food. 14, 1023-31 (2011)
PubMed link      E-mail link

Reference Number: 1600
Lee YH, Morrison BL, Bottaro DP. Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J Biol Chem. 289, 20448-61 (2014)
PubMed link      E-mail link

Reference Number: 1623
Du T, Ju G, Wu S, Cheng Z, Cheng J, Zou X, Zhang G, Miao S, Liu G, Zhu Y. Microvesicles derived from human Wharton's jelly mesenchymal stem cells promote human renal cancer cell growth and aggressiveness through induction of hepatocyte growth factor. PLoS One. 9, e96836 (2014)
PubMed link      E-mail link

Leiomyosarcoma

Reference Number: 138
Rong, S. et al. Met expression and sarcoma tumorigenicity. Cancer Res 53, 5355-60 (1993).
PubMed link      E-mail link

Reference Number: 312
Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100, 12718-23 (2003)
PubMed link      E-mail link

Reference Number: 353
Jiao Y, Zhao P, Zhu J, Grabinski T, Feng Z, Guan X, Skinner RS, Gross MD, Hay RV, Tachibana H, Cao B. Construction of human naive Fab library and characterization of anti-met Fab fragment generated from the library. Mol Biotechnol. 31, 41-54 (2005)
PubMed link      E-mail link

Liver

Reference Number: 70
Bilezikci, B., Haberal, A. N. & Demirhan, B. Hepatocyte growth factor in patients with three different stages of chronic liver disease including hepatocellular carcinoma, cirrhosis and chronic hepatitis: an immunohistochemical study. Can J Gastroenterol 15, 159-65 (2001).
PubMed link      E-mail link

Reference Number: 71
Guirouilh, J. et al. Expression of hepatocyte growth factor in human hepatocellular carcinoma. J Hepatol 34, 78-83 (2001).
PubMed link      E-mail link

Reference Number: 72
Kiss, A., Wang, N. J., Xie, J. P. & Thorgeirsson, S. S. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 3, 1059-66 (1997).
PubMed link      E-mail link

Reference Number: 73
Ljubimova, J. Y., Petrovic, L. M., Wilson, S. E., Geller, S. A. & Demetriou, A. A. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 45, 79-87 (1997).
PubMed link      E-mail link

Reference Number: 74
Schoedel, K. E., Tyner, V. Z., Kim, T. H., Michalopoulos, G. K. & Mars, W. M. HGF, MET, and Matrix-Related Proteases in Hepatocellular Carcinoma, Fibrolamellar Variant, Cirrhotic and Normal Liver. Mod Pathol 16, 14-21 (2003).
PubMed link      E-mail link

Reference Number: 450
Osada S, Kanematsu M, Imai H, Goshima S, Sugiyama Y. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg. 201, 405-11 (2005)
PubMed link      E-mail link

Reference Number: 468
Yang H, Magilnick N, Noureddin M, Mato JM, Lu SC. Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density-dependent in HepG2 cells. J Cell Physiol. 210, 766-73 (2007)
PubMed link      E-mail link

Reference Number: 474
Nakanishi C, Moriuchi A, Ido A, Numata M, Kim ID, Kusumoto K, Hasuike S, Abe H, Nagata K, Akiyama Y, Uto H, Kataoka H, Tsubouchi H. Effect of hepatocyte growth factor on endogenous hepatocarcinogenesis in rats fed a choline-deficient L-amino acid-defined diet. Oncol Rep. 16 25-31 (2006)
PubMed link      E-mail link

Reference Number: 477
Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy. Dig Liver Dis. 38, 490-7 (2006)
PubMed link      E-mail link

Reference Number: 478
Lasagna N, Fantappie O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res. 66, 2673-82 (2006)
PubMed link      E-mail link

Reference Number: 566
Hu RH, Ho MC, Wu YM, Lee PH. Peritoneal fluid contains high concentration of hepatocyte growth factor and vascular endothelial growth factor after resection for hepatocellular carcinoma. Hepatogastroenterology. 54, 862-5 (2007)
PubMed link      E-mail link

Reference Number: 573
Isbert C, Ritz JP, Roggan A, Schuppan D, Ajubi N, Buhr HJ, Hohenberger W, Germer CT. Laser-induced thermotherapy (LITT) elevates mRNA expression of connective tissue growth factor (CTGF) associated with reduced tumor growth of liver metastases compared to hepatic resection. Lasers Surg Med. 39, 42-50 (2007)
PubMed link      E-mail link

Reference Number: 589
Kopitz C, Gerg M, Bandapalli OR, Ister D, Pennington CJ, Hauser S, Flechsig C, Krell HW, Antolovic D, Brew K, Nagase H, Stangl M, von Weyhern CW, Brücher BL, Brand K, Coussens LM, Edwards DR, Krüger A. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res. 67, 8615-23 (2007)
PubMed link      E-mail link

Reference Number: 632
Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, Factor VM, Thorgeirsson SS. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res. 67, 9844-51 (2007)
PubMed link      E-mail link

Reference Number: 645
Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, Eun JY, Kim HG, Yoon SS, Lee DS, Kim JH, Kim JR. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis. 25, 89-96 (2008)
PubMed link      E-mail link

Reference Number: 659
Shirako E, Hirayama N, Tsukada Y, Tanaka T, Kitamura N. Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor-induced inhibition of HepG2 hepatoma cell proliferation. J Cell Biochem. 104, 176-88 (2008)
PubMed link      E-mail link

Reference Number: 662
Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, Bichler C, Kandioler D, Wrba F, Mikulits W, Gerner C, Shehata M, Majdic O, Streubel B, Berger W, Micksche M, Zatloukal K, Schulte-Hermann R, Grasl-Kraupp B. New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. Br J Cancer. 99, 151-9 (2008)
PubMed link      E-mail link

Reference Number: 665
Rui C, Li C, Xu W, Zhan Y, Li Y, Yang X. Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells. Biochem J. 411, 379-86 (2008)
PubMed link      E-mail link

Reference Number: 681
Chau GY, Lui WY, Chi CW, Chau YP, Li AF, Kao HL, Wu CW. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection. Eur J Surg Oncol. 34, 333-8 (2008)
PubMed link      E-mail link

Reference Number: 701
Abdel Aziz MT, El-Miligy D, Amin MA, El Ansari A, Ahmed HH, Marzouk S, Sabry D. Molecular evaluation of apoptotic versus antiapoptotic angiogenic markers in hepatocellular carcinoma. Clin Biochem41, 1008-14 (2008) Epub 2008 Feb 21
PubMed link      E-mail link

Reference Number: 722
Justinger C, Schlüter C, Oliviera-Frick V, Kopp B, Rubie C, Schilling MK. Increased growth factor expression after hepatic and pancreatic resection. Oncol Rep. 20, 1527-31 (2008)
PubMed link      E-mail link

Reference Number: 852
Piscaglia AC, Shupe TD, Pani G, Tesori V, Gasbarrini A, Petersen BE. Establishment of cancer cell lines from rat hepatocholangiocarcinoma and assessment of the role of granulocyte-colony stimulating factor and hepatocyte growth factor in their growth, motility and survival. J Hepatol. 51, 77-92 (2009)
PubMed link      E-mail link

Reference Number: 902
Wang Z, Ge L, Wang M, Carr BI. Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5. Hepatology. 46, 2003-13 (2007)
PubMed link      E-mail link

Reference Number: 904
Lee KH, Kim JR. Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells. Clin Exp Metastasis. 26, 685-92 (2009)
PubMed link      E-mail link

Reference Number: 906
Grotegut S, Kappler R, Tarimoradi S, Lehembre F, Christofori G, Von Schweinitz D. Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation. Int J Oncol. 36, 1261-7 (2010)
PubMed link      E-mail link

Reference Number: 908
Mu Z, Wang H, Zhang J, Li Q, Wang L, Guo X. KAI1/CD82 suppresses hepatocyte growth factor-induced migration of hepatoma cells via upregulation of Sprouty2. Sci China C Life Sci. 51, 648-54 (2008)
PubMed link      E-mail link

Reference Number: 938
Schrötzlmair F, Kopitz C, Halbgewachs B, Lu F, Algül H, Brünner N, Gänsbacher B, Krüger A. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator. J Cell Mol Med. 14, 2760-70 (2010)
PubMed link      E-mail link

Reference Number: 946
Kubo E, Yoshikawa N, Kunitomo M, Kagota S, Shinozuka K, Nakamura K. Inhibitory effect of Cordyceps sinensis on experimental hepatic metastasis of melanoma by suppressing tumor cell invasion. Anticancer Res. 30, 3429-33 (2010)
PubMed link      E-mail link

Reference Number: 1026
Gu K, Lai ST, Ma NY, Zhao JD, Ren ZG, Wang J, Liu J, Jiang GL. Hepatic regeneration after sublethal partial liver irradiation in cirrhotic rats. J Radiat Res. 52, 582-91 (2011)
PubMed link      E-mail link

Reference Number: 1161
Wang YC, Xu GL, Jia WD, Han SJ, Ren WH, Wang W, Liu WB, Zhang CH, Chen H. Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression. Inflammation. 35, 143-9 (2012)
PubMed link      E-mail link

Reference Number: 1200
Huang FI, Chen YL, Chang CN, Yuan RH, Jeng YM. Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion. Carcinogenesis. 33, 1142-8 (2012)
PubMed link      E-mail link

Reference Number: 1368
Ang CS, Sun MY, Huitzil-Melendez DF, Chou JF, Capanu M, Jarnagin W, Fong Y, Dematteo RP, D'Angelica M, Allen P, Chen CT, O'Reilly EM, Weiser MR, Abou-Alfa GK. c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival. Anticancer Res. 33, 3241-5 (2013)
PubMed link      E-mail link

Reference Number: 1385
Liu XL, Li FQ, Liu LX, Li B, Zhou ZP. TNF-a, HGF and macrophage in peritumoural liver tissue relate to major risk factors of HCC Recurrence. Hepatogastroenterology. 60, 1121-6 (2013)
PubMed link      E-mail link

Reference Number: 1386
Ogunwobi OO1, Puszyk W, Dong HJ, Liu C. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One. 8, e63765 (2013)
PubMed link      E-mail link

Reference Number: 1387
Tanahashi T1, Osada S, Yamada A, Kato J, Yawata K, Mori R, Imai H, Sasaki Y, Saito S, Tanaka Y, Nonaka K, Yoshida K. Extracellular signal-regulated kinase and Akt activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition. Int J Oncol. 42, 556-64 (2013)
PubMed link      E-mail link

Reference Number: 1400
Costantini S1, Capone F, Maio P, Guerriero E, Colonna G, Izzo F, Castello G. Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma. Oncol Rep. 29, 2163-8 (2013)
PubMed link      E-mail link

Reference Number: 1425
Yang X1, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH, Qin LX. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 59, 1874-85 (2014)
PubMed link      E-mail link

Reference Number: 1426
Li X1, Bian Y, Takizawa Y, Hashimoto T, Ikoma T, Tanaka J, Kitamura N, Inagaki Y, Komada M, Tanaka T. ERK-dependent downregulation of Skp2 reduces Myc activity with HGF, leading to inhibition of cell proliferation through a decrease in Id1 expression. Mol Cancer Res. 11, 1437-47 (2013)
PubMed link      E-mail link

Reference Number: 1476
Yu G, Jing Y, Kou X, Ye F, Gao L, Fan Q, Yang Y, Zhao Q, Li R, Wu M, Wei L. Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma. PLoS One. 8, e73312 (2013)
PubMed link      E-mail link

Reference Number: 1481
Karabulut S, Tas F, Akyüz F, Ormeci AC, Serilmez M, Soydinç HO, Vatansever S, Yasasever V. Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma. Tumour Biol. 35, 2327-33 (2014)
PubMed link      E-mail link

Reference Number: 1496
Jia CC, Wang TT, Liu W, Fu BS, Hua X, Wang GY, Li TJ, Li X, Wu XY, Tai Y, Zhou J, Chen GH, Zhang Q. Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS One. 8, e63243 (2013)
PubMed link      E-mail link

Reference Number: 1526
Muñoz Ú, Puche JE, Hannivoort R, Lang UE, Cohen-Naftaly M, Friedman SL. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol Cancer Res. 10, 1216-27 (2012)
PubMed link      E-mail link

Lung

Reference Number: 88
Eagles, G. et al. Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients. Br J Cancer 73, 377-81 (1996).
PubMed link      E-mail link

Reference Number: 89
Harvey, P. et al. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J Pathol 180, 389-94 (1996).
PubMed link      E-mail link

Reference Number: 90
Olivero, M. et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 74, 1862-8 (1996).
PubMed link      E-mail link

Reference Number: 91
Tsao, M. S., Yang, Y., Marcus, A., Liu, N. & Mou, L. Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. Hum Pathol 32, 57-65. (2001).
PubMed link      E-mail link

Reference Number: 246
Wislez M, Rabbe N, Marchal J, Milleron B, Crestani B, Mayaud C, Antoine M, Soler P, Cadranel J. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res 63:1405-12 (2003).
PubMed link      E-mail link

Reference Number: 247
Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio PM, Flavia Di Renzo M. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 288:382-9 (2003).
PubMed link      E-mail link

Reference Number: 319
Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT, Salgia R. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 24, 1031-8 (2004
PubMed link      E-mail link

Reference Number: 320
Masuya D, Huang C, Liu D, Nakashima T, Kameyama K, Haba R, Ueno M, Yokomise H. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 90, 1555-62 (2004)
PubMed link      E-mail link

Reference Number: 369
Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem. 281, 13005-8 (2006)
PubMed link      E-mail link

Reference Number: 387
Stabile LP, Lyker JS, Land SR, Dacic S, Zamboni BA, Siegfried JM. Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis. Mar 2; [Epub ahead of print] (2006)
PubMed link      E-mail link

Reference Number: 394
Hakuma N, Kinoshita I, Shimizu Y, Yamazaki K, Yoshida K, Nishimura M, Dosaka-Akita H. E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells. Cancer Res. 65, 10776-82 (2005)
PubMed link      E-mail link

Reference Number: 395
Sugimoto T, Takiguchi Y, Kurosu K, Kasahara Y, Tanabe N, Tatsumi K, Hiroshima K, Minamihisamatsu M, Miyamoto T, Kuriyama T. Growth factor-mediated interaction between tumor cells and stromal fibroblasts in an experimental model of human small-cell lung cancer. Oncol Rep. 14, 823-30 (2005)
PubMed link      E-mail link

Reference Number: 438
Chen JT, Lin TS, Chow KC, Huang HH, Chiou SH, Chiang SF, Chen HC, Chuang TL, Lin TY, Chen CY. Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol. 34, 264-73 (2006)
PubMed link      E-mail link

Reference Number: 570
Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, Fukayama M. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 98, 1006-13 (2007)
PubMed link      E-mail link

Reference Number: 601
Chen JT, Huang CY, Chiang YY, Chen WH, Chiou SH, Chen CY, Chow KC. HGF Increases Cisplatin Resistance via Down-Regulation of AIF in Lung Cancer Cells. Am J Respir Cell Mol Biol. 38, 559-65 (2008)
PubMed link      E-mail link

Reference Number: 602
Pierce A, Barron N, Linehan R, Ryan E, O'Driscoll L, Daly C, Clynes M. Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines. Eur J Cancer. 44, 151-9 (2008)
PubMed link      E-mail link

Reference Number: 692
Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68, 9479-87 (2008)
PubMed link      E-mail link

Reference Number: 798
Wang X, Li K, Chen H, Wang D, Zhang Y, Bai C. Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer? J Cell Mol Med. 14, 833-9 (2010)
PubMed link      E-mail link

Reference Number: 932
Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther. 9, 2785-92 (2010)
PubMed link      E-mail link

Reference Number: 937
Argast GM, Mercado P, Mulford IJ, O'Connor M, Keane DM, Shaaban S, Epstein DM, Pachter JA, Kan JL. Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-ß enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs. 193, 114-32 (2011)
PubMed link      E-mail link

Reference Number: 944
Korobko IV, Zinov'eva MV, Allakhverdiev AK, Zborovskaia IB, Svwrdlov ED. [c-Met and HGF expression in non-small-cell lung carcinomas]. Mol Gen Mikrobiol Virusol. 18-21 (2007)
PubMed link      E-mail link

Reference Number: 945
Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, Laccabue D, Supino R, Belluco S, Favini E, Poletti A, Zunino F. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther. 5, 2388-97 (2006)
PubMed link      E-mail link

Reference Number: 1070
Tretiakova M, Salama AK, Karrison T, Ferguson MK, Husain AN, Vokes EE, Salgia R. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 30, 341-54 (2011)
PubMed link      E-mail link

Reference Number: 1074
Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res. 17, 2260-9 (2011)
PubMed link      E-mail link

Reference Number: 1075
Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S, Hirata K. Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs. Int J Cancer. 129, 1410-6 (2011)
PubMed link      E-mail link

Reference Number: 1077
Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K, Yasumoto K. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol. 5, 591-6 (2010)
PubMed link      E-mail link

Reference Number: 1079
Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 17, 77-88 (2010)
PubMed link      E-mail link

Reference Number: 1080
Yamamoto BJ, Elias PD, Masino JA, Hudson BD, McCoy AT, Anderson ZJ, Varnum MD, Sardinia MF, Wright JW, Harding JW. The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J Pharmacol Exp Ther. 333, 161-73 (2010)
PubMed link      E-mail link

Reference Number: 1081
Navab R, Liu J, Seiden-Long I, Shih W, Li M, Bandarchi B, Chen Y, Lau D, Zu YF, Cescon D, Zhu CQ, Organ S, Ibrahimov E, Ohanessian D, Tsao MS. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia. 11, 1292-300 (2009)
PubMed link      E-mail link

Reference Number: 1082
Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res. 16, 174-83
PubMed link      E-mail link

Reference Number: 1083
Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 15, 6630-8 (2009)
PubMed link      E-mail link

Reference Number: 1085
Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69, 8009-16 (2009)
PubMed link      E-mail link

Reference Number: 1089
Kishi Y, Kuba K, Nakamura T, Wen J, Suzuki Y, Mizuno S, Nukiwa T, Matsumoto K, Nakamura T. Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci. 100, 1351-8 (2009)
PubMed link      E-mail link

Reference Number: 1090
. Epub 2009 May 12. Kishi Y, Kuba K, Nakamura T, Wen J, Suzuki Y, Mizuno S, Nukiwa T, Matsumoto K, Nakamura T. Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci. 100, 1351-8 (2009)
PubMed link      E-mail link

Reference Number: 1092
Kubota T, Taiyoh H, Matsumura A, Murayama Y, Ichikawa D, Okamoto K, Fujiwara H, Ikoma H, Nakanishi M, Kikuchi S, Sakakura C, Ochiai T, Kokuba Y, Taniguchi H, Sonoyama T, Matsumoto K, Nakamura T, Otsuji E. NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells. Clin Exp Metastasis. 26, 447-56 (2009)
PubMed link      E-mail link

Reference Number: 1093
Chiang YY. Hepatocyte growth factor induces hypoxia-related interleukin-8 expression in lung adenocarcinoma cells. Mol Carcinog. 48, 662-70 (2009)
PubMed link      E-mail link

Reference Number: 1104
Han JY, Kim JY, Lee SH, Yoo NJ, Choi BG. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung Cancer. 74, 293-9 (2011)
PubMed link      E-mail link

Reference Number: 1151
Hosoda H, Izumi H, Tukada Y, Takagiwa J, Chiaki T, Yano M, Arai H. Plasma hepatocyte growth factor elevation may be associated with early metastatic disease in primary lung cancer patients. Ann Thorac Cardiovasc Surg. 18, 1-7 (2012)
PubMed link      E-mail link

Reference Number: 1168
Tachibana K, Minami Y, Shiba-Ishii A, Kano J, Nakazato Y, Sato Y, Goya T, Noguchi M. Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. Lung Cancer. 75, 181-8 (2012)
PubMed link      E-mail link

Reference Number: 1170
Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol. 6, 2011-7 (2011)
PubMed link      E-mail link

Reference Number: 1216
Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol. 7, 1078-85 (2012)
PubMed link      E-mail link

Reference Number: 1217
Ujiie H, Tomida M, Akiyama H, Nakajima Y, Okada D, Yoshino N, Takiguchi Y, Tanzawa H. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res. 32, 3251-8 (2012)
PubMed link      E-mail link

Reference Number: 1220
Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. Anticancer Res. 32, 3785-90 (2012)
PubMed link      E-mail link

Reference Number: 1229
Liu Y, Yang Y, Ye YC, Shi QF, Chai K, Tashiro S, Onodera S, Ikejima T. Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells. J Pharmacol Sci. 118, 423-32 (2012)
PubMed link      E-mail link

Reference Number: 1291
Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 11, 2149-57 (2012)
PubMed link      E-mail link

Reference Number: 1366
Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 8, e62104 (2013)
PubMed link      E-mail link

Reference Number: 1402
Casaluce F1, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol. 8, 55-67 (2013)
PubMed link      E-mail link

Reference Number: 1437
Ramanujum R1, Lin YL, Liu JK, He S. Regulatory expression of MMP-8/MMP-9 and inhibition of proliferation, migration and invasion in human lung cancer A549 cells in the presence of HGF variants. Kaohsiung J Med Sci. 29, 530-9 (2013)
PubMed link      E-mail link

Reference Number: 1495
Telega A, Kos-Kudla B, Foltyn W, Blicharz-Dorniak J, Rosiek V. Selected neuroendocrine tumour markers, growth factors and their receptors in typical and atypical bronchopulmonary carcinoids. Endokrynol Pol. 63, 477-82 (2012)
PubMed link      E-mail link

Reference Number: 1506
Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 8, e62104 (2013)
PubMed link      E-mail link

Reference Number: 1514
Wu W, Bi C, Credille KM, Manro JR, Peek VL, Donoho GP, Yan L, Wijsman JA, Yan SB, Walgren RA. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. Clin Cancer Res. 19, 5699-710 (2013)
PubMed link      E-mail link

Reference Number: 1515
Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Anticancer Drugs. 24, 1039-46 (2013)
PubMed link      E-mail link

Reference Number: 1553
Johnson H, Lescarbeau RS, Gutierrez JA, White FM. Phosphotyrosine profiling of NSCLC cells in response to EGF and HGF reveals network specific mediators of invasion. J Proteome Res. 12, 1856-67 (2013)
PubMed link      E-mail link

Reference Number: 1636
Fang MY, Wang SY, Zheng YB, Gong LY, Bao WL, Gu DL, Mao WM. Prognostic and predictive significance of plasma hepatocyte growth factor and carcinoembryonic antigen in non-small lung cancer after surgery. Eur Rev Med Pharmacol Sci. 18, 398-403 (2014)
PubMed link      E-mail link

Reference Number: 1670
Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Lung Cancer. 86, 195-200 (2014)
PubMed link      E-mail link

Reference Number: 1708
Cañadas I, Taus A, González I, Villanueva X, Gimeno J, Pijuan L, Dómine M, Sánchez-Font A, Vollmer I, Menéndez S, Arpí O, Mojal S, Rojo F, Rovira A, Albanell J, Arriola E High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients. Oncotarget. 5, 5246-56 (2014)
PubMed link      E-mail link

Reference Number: 1722
Zhang N, Xie F, Gao W, Yu S, Qiu L, Lin W, Sun Y, Jia T Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis. Mol Med Rep. 11, 2797-804 (2015)
PubMed link      E-mail link

Reference Number: 1725
Umeguchi H, Sueoka-Aragane N, Kobayashi N, Nakamura T, Sato A, Takeda Y, Hayashi S, Sueoka E, Kimura S Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Oncol Rep. 33, 391-6 (2015)
PubMed link      E-mail link

Reference Number: 1777
Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression. Mol Cancer Ther. 14, 533-41 (2015)
PubMed link      E-mail link

Reference Number: 1779
Wu H, Fan F, Liu Z, Shen C, Wang A, Lu Y. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway. Cancer Chemother Pharmacol. 76, 307-15 (2015)
PubMed link      E-mail link

Reference Number: 1885
Yu H, Wang Y, Yu Q, Zhang H, Ma W, Shang S, Wang D Significance of plasma hepatocyte growth factor in diagnosis of benign and malignant solitary pulmonary nodules. Int J Clin Exp Pathol. 8, 2063-7 (2015)
PubMed link      E-mail link

Lymphomas

Reference Number: 88
Eagles, G. et al. Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients. Br J Cancer 73, 377-81 (1996).
PubMed link      E-mail link

Reference Number: 172
Capello, D. et al. The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. Leukemia 14, 285-91. (2000).
PubMed link      E-mail link

Reference Number: 173
Gaidano, G. et al. Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease. J Clin Virol 16, 215-24. (2000).
PubMed link      E-mail link

Reference Number: 174
Hsiao, L. T. et al. High serum hepatocyte growth factor level in patients with non- Hodgkin's lymphoma. Eur J Haematol 70, 282-9. (2003).
PubMed link      E-mail link

Reference Number: 175
Weimar, I. S. et al. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood 89, 990-1000. (1997).
PubMed link      E-mail link

Reference Number: 268
Hsiao LT, Lin JT, Yu IT, Chiou TJ, Liu JH, Yen CC, Wang WS, Chen PM. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma. Eur J Maematol 70:282-9 (2003).
PubMed link      E-mail link

Reference Number: 429
Tjin EP, Groen RW, Vogelzang I, Derksen PW, Klok MD, Meijer HP, van Eeden S, Pals ST, Spaargaren M. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood107, 760-8 (2006)
PubMed link      E-mail link

Reference Number: 431
Toyama T, Ido A, Sasak H, Maeda K, Yamashita K, Kubuki Y, Suzuki M, Matsuoka H, Tsubouchi H. Possible involvement of neutrophils in a serum level increase of hepatocyte growth factor in non-Hodgkin's lymphoma. Oncol Rep. 13, 439-44 (2005)
PubMed link      E-mail link

Reference Number: 432
Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sorensen FB, Abildgaard N. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol. 128, 210-7 (2005)
PubMed link      E-mail link

Reference Number: 434
Tjin EP, Bende RJ, Derksen PW, van Huijstee AP, Kataoka H, Spaargaren M, Pals ST. Follicular dendritic cells catalyze hepatocyte growth factor (HGF) activation in the germinal center microenvironment by secreting the serine protease HGF activator. Immunol. 175, 2807-13 (2005)
PubMed link      E-mail link

Reference Number: 530
Passam FH, Alexandrakis MG, Moschandrea J, Sfiridaki A, Roussou PA, Siafakas NM. Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis. Int J Immunopathol Pharmacol. 19, 161-70 (2006)
PubMed link      E-mail link

Reference Number: 630
Etto L, Lacerda E, Baiocchi O, Silva V, Dalboni M, Alves A, Silva M, Vettore A, Colleoni G. Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. Leuk Lymphoma. 49, 257-64 (2008)
PubMed link      E-mail link

Reference Number: 713
Ria R, Cirulli T, Giannini T, Bambace S, Serio G, Portaluri M, Ribatti D, Vacca A, Dammacco F. Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas. Clin Exp Med. 8,141-5 (2008) Epub 2008 Sep 13
PubMed link      E-mail link

Reference Number: 1149
Secchiero P, Corallini F, Zavan B, Tripodo C, Vindigni V, Zauli G. Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Invest New Drugs. 30, 803-7 (2012)
PubMed link      E-mail link

Melanoma

Reference Number: 202
Hendrix, M. J. et al. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol 152, 855-63. (1998).
PubMed link      E-mail link

Reference Number: 338
Nambiar S, Mirmohammadsadegh A, Doroudi R, Gustrau A, Marini A, Roeder G, Ruzicka T, Hengge UR.Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays. Arch Dermatol. 141, 165-73 (2005)
PubMed link      E-mail link

Reference Number: 412
Wolnicka-Glubisz A, Noonan FP. Neonatal susceptibility to UV induced cutaneous malignant melanoma in a mouse model. Photochem Photobiol Sci. 5 254-60 (2006)
PubMed link      E-mail link

Reference Number: 419
Poon VK, Huang L, Burd A. Biostimulation of dermal fibroblast by sublethal Q-switched Nd:YAG 532 nm laser: collagen remodeling and pigmentation. J Photochem Photobiol B. 81, 1-8 (2005)
PubMed link      E-mail link

Reference Number: 420
Cools-Lartigue J, Marshall JC, Caissie AL, Saraiva VS, Burnier MN Jr. Secretion of hepatocyte growth factor and vascular endothelial growth factor during uveal melanoma-monocyte in vitro interactions. Melanoma Res.15, 141-5 (2005)
PubMed link      E-mail link

Reference Number: 523
Gao L, Feng Y, Bowers R, Becker-Hapak M, Gardner J, Council L, Linette G, Zhao H, Cornelius LA. Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res. 66, 7880-8 (2006)
PubMed link      E-mail link

Reference Number: 524
Tormo D, Ferrer A, Gaffal E, Wenzel J, Basner-Tschakarjan E, Steitz J, Heukamp LC, Gütgemann I, Buettner R, Malumbres M, Barbacid M, Merlino G, Tüting T. Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol. 169, 665-72 (2006)
PubMed link      E-mail link

Reference Number: 525
Tormo D, Ferrer A, Bosch P, Gaffal E, Basner-Tschakarjan E, Wenzel J, Tüting T. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res. 66, 5427-35 (2006)
PubMed link      E-mail link

Reference Number: 543
Gaggioli C, Deckert M, Robert G, Abbe P, Batoz M, Ehrengruber MU, Ortonne JP, Ballotti R, Tartare-Deckert S. HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. Oncogene. 24, 1423-33 (2005)
PubMed link      E-mail link

Reference Number: 869
Damm S, Koefinger P, Stefan M, Wels C, Mehes G, Richtig E, Kerl H, Otte M, Schaider H. HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta. J Invest Dermatol. 130, 1893-903 (2010)
PubMed link      E-mail link

Reference Number: 871
Topcu-Yilmaz P, Kiratli H, Saglam A, Söylemezoglu F, Hascelik G. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res. 20, 126-32 (2010)
PubMed link      E-mail link

Reference Number: 883
Oka M, Kikkawa U, Nishigori C. Protein kinase C-betaII represses hepatocyte growth factor-induced invasion by preventing the association of adapter protein Gab1 and phosphatidylinositol 3-kinase in melanoma cells. J Invest Dermatol. 128, 188-95 (2008)
PubMed link      E-mail link

Reference Number: 1206
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 487, 500-4 (2012)
PubMed link      E-mail link

Reference Number: 1207
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 487, 505-9 (2012)
PubMed link      E-mail link

Reference Number: 1535
Kwon MJ, Kim DH, Park HR, Shin HS, Kwon JH, Lee DJ, Kim JH, Cho SJ, Nam ES. Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus-negative tonsillar squamous cell carcinoma and their prognostic significances. Hum Pathol. 45, 1327-38 (2014)
PubMed link      E-mail link

Reference Number: 1607
Lezcano C, Lee CW, Larson AR, Menzies AM, Kefford RF, Thompson JF, Mihm MC Jr, Ogino S, Long GV, Scolyer RA, Murphy GF. Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Mod Pathol. 27, 1193-202 (2014)
PubMed link      E-mail link

Reference Number: 1731
Cheng H, Terai M, Kageyama K, Ozaki S, McCue PA, Sato T, Aplin AE Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Res. 75, 2737-48 (2015)
PubMed link      E-mail link

Reference Number: 1776
Hwang S, Kim HE, Min M, Raghunathan R, Panova IP, Munshi R, Ryu B. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma. J Invest Dermatol. 135, 2283-91 (2015)
PubMed link      E-mail link

Reference Number: 1891
Fedorenko IV, Wargo JA, Flaherty KT, Messina JL, Smalley KS. BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. J Invest Dermatol. 135, 3115-24 (2015)
PubMed link      E-mail link

Mesothelioma

Reference Number: 89
Harvey, P. et al. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J Pathol 180, 389-94 (1996).
PubMed link      E-mail link

Reference Number: 211
Tolnay, E. et al. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 124, 291-6 (1998).
PubMed link      E-mail link

Reference Number: 424
Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, Strizzi L, Penengo L, Tognon M, Mutti L, Gaudino G. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci U S A. 98, 12032-7 (2001)
PubMed link      E-mail link

Reference Number: 425
Harvey P, Clark IM, Jaurand MC, Warn RM, Edwards DR. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer. 83, 1147-53 (2000)
PubMed link      E-mail link

Reference Number: 426
Thirkettle I, Harvey P, Hasleton PS, Ball RY, Warn RM. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology.  36, 522-8 (2000)
PubMed link      E-mail link

Reference Number: 427
Harvey P, Warn A, Dobbin S, Arakaki N, Daikuhara Y, Jaurand MC, Warn RM. Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology. Br J Cancer. 77, 1052-9 (1998)
PubMed link      E-mail link

Reference Number: 428
Klominek J, Baskin B, Liu Z, Hauzenberger Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor.D. Int J Cancer. 76, 240-9 (1998)
PubMed link      E-mail link

Reference Number: 797
Suzuki Y, Sakai K, Ueki J, Xu Q, Nakamura T, Shimada H, Nakamura T, Matsumoto K. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int J Cancer. 127, 1948-57 (2010)
PubMed link      E-mail link

MFH/Fibrosarcoma

Reference Number: 141
Fukuda, T. et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 48, 757-62 (1998).
PubMed link      E-mail link

Multiple Myeloma

Reference Number: 160
Borset, M., Hjorth-Hansen, H., Seidel, C., Sundan, A. & Waage, A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 88, 3998-4004 (1996).
PubMed link      E-mail link

Reference Number: 161
Borset, M., Seidel, C., Hjorth-Hansen, H., Waage, A. & Sundan, A. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk Lymphoma 32, 249-56 (1999).
PubMed link      E-mail link

Reference Number: 162
Derksen, P. W. et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17, 764-74. (2003).
PubMed link      E-mail link

Reference Number: 163
Seidel, C., Borset, M., Hjorth-Hansen, H., Sundan, A. & Waage, A. Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Med Oncol 15, 145-53 (1998).
PubMed link      E-mail link

Reference Number: 164
Seidel, C. et al. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 119, 672-6 (2002).
PubMed link      E-mail link

Reference Number: 165
Turesson, I. et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 106, 1005-12 (1999).
PubMed link      E-mail link

Reference Number: 166
Seidel, C. et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 91, 806-12 (1998).
PubMed link      E-mail link

Reference Number: 266
Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 72:229-33 (2003).
PubMed link      E-mail link

Reference Number: 267
Urba ska-Rys H, Wierzbowska A, Robak T. Circulating angiogenic cytokines in multiple myeloma and related disorders. Eur Cytokine Netw 14:40-51 (2003).
PubMed link      E-mail link

Reference Number: 268
Hsiao LT, Lin JT, Yu IT, Chiou TJ, Liu JH, Yen CC, Wang WS, Chen PM. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma. Eur J Maematol 70:282-9 (2003).
PubMed link      E-mail link

Reference Number: 302
Tjin EP, Derksen PW, Kataoka H, Spaargaren M, Pals ST. Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood 104, 2172-5 (2004)
PubMed link      E-mail link

Reference Number: 303
Vande Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, Van Camp B, Van Riet I. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 18, 976-82 (2004)
PubMed link      E-mail link

Reference Number: 429
Tjin EP, Groen RW, Vogelzang I, Derksen PW, Klok MD, Meijer HP, van Eeden S, Pals ST, Spaargaren M. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood107, 760-8 (2006)
PubMed link      E-mail link

Reference Number: 430
Holt RU, Baykov V, Ro TB, Brabrand S, Waage A, Sundan A, Borset M. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica. 90, 436 (2005)
PubMed link      E-mail link

Reference Number: 432
Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sorensen FB, Abildgaard N. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol. 128, 210-7 (2005)
PubMed link      E-mail link

Reference Number: 514
Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood. 109, 3024-30 (2007)
PubMed link      E-mail link

Reference Number: 515
Kara IO, Sahin B, Gunesacar R, Unsal C. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma. Adv Ther. 23, 635-45 (2006)
PubMed link      E-mail link

Reference Number: 552
Alexandrakis MG, Sfiridaki A, Miyakis S, Pappa C, Kandidaki E, Alegakis A, Margioris AN. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clin Chim Acta. 379, 31-5 (2007)
PubMed link      E-mail link

Reference Number: 810
Pour L, Svachova H, Adam Z, Mikulkova Z, Buresova L, Kovarova L, Buchler T, Penka M, Vorlicek J, Hajek R. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma. 57, 29-34 (2010)
PubMed link      E-mail link

Reference Number: 812
Wader KF, Fagerli UM, Holt RU, Stordal B, Børset M, Sundan A, Waage A. Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. Eur J Haematol. 81, 380-3 (2008)
PubMed link      E-mail link

Reference Number: 813
Zdzisinska B, Bojarska-Junak A, Dmoszynska A, Kandefer-Szerszen M. Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz). 56, 207-21 (2008)
PubMed link      E-mail link

Reference Number: 997
Purdue MP, Lan Q, Menashe I, Zheng T, Zhang Y, Yeager M, Hosgood HD 3rd, Zahm SH, Chanock SJ, Rothman N, Baris D. Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol. 29, 42-6 (2011)
PubMed link      E-mail link

Reference Number: 1036
Akkök CA, Hervig T, Stamnesfet S, Nesthus I, Melve GK, Lassalle P, Bruserud O. Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma. Cytotherapy. 13, 1259-68 (2011)
PubMed link      E-mail link

Reference Number: 1286
Bonanno G, Mariotti A, Procoli A, Folgiero V, Natale D, De Rosa L, Majolino I, Novarese L, Rocci A, Gambella M, Ciciarello M, Scambia G, Palumbo A, Locatelli F, De Cristofaro R, Rutella S. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. J Transl Med. 10, 247 (2012)
PubMed link      E-mail link

Reference Number: 1299
Tsirakis G, Pappa CA, Psarakis FE, Fragioudaki M, Tsioutis C, Stavroulaki E, Boula A, Alexandrakis MG. Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma. Med Oncol. 29, 2396-401 (2012)
PubMed link      E-mail link

Reference Number: 1304
Tsirakis G, Pappa CA, Kaparou M, Boula A, Katsomitrou V, Xekalou A, Kyriakaki S, Alexandrakis MG. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma. Tumour Biol. 34, 859-64 (2013)
PubMed link      E-mail link

Reference Number: 1330
Kristensen IB, Christensen JH, Lyng MB, Møller MB, Pedersen L, Rasmussen LM, Ditzel HJ, Abildgaard N. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. Br J Haematol. 161, 373-82 (2013)
PubMed link      E-mail link

Reference Number: 1533
Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 6, 92 (2013)
PubMed link      E-mail link

Reference Number: 1653
Ferrucci A, Moschetta M, Frassanito MA, Berardi S, Catacchio I, Ria R, Racanelli V, Caivano A, Solimando AG, Vergara D, Maffia M, Latorre D, Rizzello A, Zito A, Ditonno P, Maiorano E, Ribatti D, Vacca A. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target. Clin Cancer Res. 20, 5796-807 (2014)
PubMed link      E-mail link

Reference Number: 1790
Andersen NF, Kristensen IB, Preiss BS, Christensen JH, Abildgaard N Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis. Eur J Haematol. 95, 211-7 (2015)
PubMed link      E-mail link

Reference Number: 1791
Abraham J, Desport E, Rigaud C, Marin B, Bender S, Lacombe C, Moreau S, Yagoubi F, Bordessoule D, Lavergne D, Bridoux F, Jaccard A Hepatocyte growth factor measurement in AL amyloidosis. Amyloid. 22, 112-6 (2015)
PubMed link      E-mail link

Nasopharyngeal

Reference Number: 104
Qian, C. N. et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62, 589-96 (2002).
PubMed link      E-mail link

Reference Number: 596
Li Z, Lin SX, Liang HZ, He JH. [Expression of hepatocyte growth factor/c-Met system in nasopharyngeal carcinoma and its biological significance]
[Article in Chinese] Zhonghua Bing Li Xue Za Zhi. 34, 75-9 (2005)

PubMed link      E-mail link

Reference Number: 709
Lim YC, Park HY, Hwang HS, Kang SU, Pyun JH, Lee MH, Choi EC, Kim CH. (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett. 271, 140-52 (2008) Epub 2008 Jul 15
PubMed link      E-mail link

Reference Number: 795
Xie LQ, Bian LJ, Li Z, Li Y, Liang YJ. Co-elevated expression of hepatocyte growth factor and Interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma. Oncol Rep. 23, 141-50 (2010)
PubMed link      E-mail link

Reference Number: 796
Li-juan B, Bing L, Zhi L, Yang L, Ying-jie L. Hepatocyte growth factor suppresses tumor cell apoptosis in nasopharyngeal carcinoma by upregulating Bcl-2 protein expression. Pathol Res Pract. 205, 828-37 (2009)
PubMed link      E-mail link

Reference Number: 801
Xie LQ, Bian LJ, Li Z, Li Y, Li ZX, Li B. Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma. Ann Surg Oncol. 17, 1927-36 (2010)
PubMed link      E-mail link

Osteosarcoma

Reference Number: 141
Fukuda, T. et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 48, 757-62 (1998).
PubMed link      E-mail link

Reference Number: 820
Chattopadhyay N, MacLeod RJ, Tfelt-Hansen J, Brown EM. 1alpha,25(OH)2-vitamin D3 inhibits HGF synthesis and secretion from MG-63 human osteosarcoma cells. Am J Physiol Endocrinol Metab. 284, E219-27 (2003)
PubMed link      E-mail link

Reference Number: 821
Fieten H, Spee B, Ijzer J, Kik MJ, Penning LC, Kirpensteijn J. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. Vet Pathol. 46, 869-77 (2009)
PubMed link      E-mail link

Reference Number: 990
Tsubaki M, Yamazoe Y, Yanae M, Satou T, Itoh T, Kaneko J, Kidera Y, Moriyama K, Nishida S. Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-ß as angiogenic factors in mouse osteosarcoma. Cytokine. 54, 100-7 (2011)
PubMed link      E-mail link

Reference Number: 1128
Zhang L, Wang Y, Wang L, Cao T, Hyuga S, Sato T, Wu Y, Yamagata S, Yamagata T. Ganglioside GD1a negatively regulates hepatocyte growth factor expression through caveolin-1 at the transcriptional level in murine osteosarcoma cells. Biochim Biophys Acta. 1810, 759-68 (2011)
PubMed link      E-mail link

Reference Number: 1805
Husmann K, Ducommun P, Sabile AA, Pedersen EM, Born W, Fuchs B. Signal transduction and downregulation of C-MET in HGF stimulated low and highly metastatic human osteosarcoma cells. Biochem Biophys Res Commun. 464, 1222-7 (2015)
PubMed link      E-mail link

Ovarian

Reference Number: 301
Wong AS, Roskelley CD, Pelech S, Miller D, Leung PC, Auersperg N. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res. 299, 248-56 (2004)
PubMed link      E-mail link

Reference Number: 322
Baykal C, Demirtas E, Al A, Ayhan A, Yuce K, Tulunay G, Kose MF, Ayhan A. Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Cynecol Cancer 14, 152-6 (2004)
PubMed link      E-mail link

Reference Number: 323
Baykal C, Demirtas E, Al A, Ayhan A, Yuce K, Tulunay G, Kose MF, Ayhan A. Comparison of HGF (hepatocyte growth factor) levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Gynecol Cancer 13, 771-5 (2003)
PubMed link      E-mail link

Reference Number: 379
Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 390, 125-36 (2005)
PubMed link      E-mail link

Reference Number: 401
Zhou HY, Wong AS. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology. 147, 2557-66. Epub 2006 Feb 9. (2006)
PubMed link      E-mail link

Reference Number: 437
Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakansson L, Groenewegen G, Lawrance J, Tang M, Wauk L, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer (EORTC). Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer.  41, 555-63(2005)
PubMed link      E-mail link

Reference Number: 500
Olivero M, Ruggiero T, Saviozzi S, Rasola A, Coltella N, Crispi S, Di Cunto F, Calogero R, Di Renzo MF. Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin. Mol Cancer Ther. 5, 1126-35 (2006)
PubMed link      E-mail link

Reference Number: 554
Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M, Di Renzo MF. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res. 13, 2191-8 (2007)
PubMed link      E-mail link

Reference Number: 635
Zhou HY, Pon YL, Wong AS. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Endocrinology. 148, 5195-208 (2007)
PubMed link      E-mail link

Reference Number: 842
Hu J, Shao S, Song Y, Zhao J, Dong Y, Gong L, Yang P. Hepatocyte growth factor induces invasion and migration of ovarian cancer cells by decreasing the expression of E-cadherin, beta-catenin, and caveolin-1. Anat Rec (Hoboken). 293, 1134-9 (2010)
PubMed link      E-mail link

Reference Number: 845
Wei W, Kong B, Yang Q, Qu X. Hepatocyte growth factor enhances ovarian cancer cell invasion through downregulation of thrombospondin-1. Cancer Biol Ther. 9, 79-87 (2010)
PubMed link      E-mail link

Reference Number: 992
Aune G, Lian AM, Tingulstad S, Torp SH, Forsmo S, Reseland JE, Stunes AK, Syversen U. Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol. 121, 402-6 (2011)
PubMed link      E-mail link

Reference Number: 1032
Goode EL, Chenevix-Trench G, Hartmann LC, Fridley BL, Kalli KR, Vierkant RA, Larson MC, White KL, Keeney GL, Oberg TN, Cunningham JM, Beesley J, Johnatty SE, Chen X, Goodman KE, Armasu SM, Rider DN, Sicotte H, Schmidt MM, Elliott EA, Høgdall E, Kjær SK, Fasching PA, Ekici AB, Lambrechts D, Despierre E, Høgdall C, Lundvall L, Karlan BY, Gross J, Brown R, Chien J, Duggan DJ, Tsai YY, Phelan CM, Kelemen LE, Peethambaram PP, Schildkraut JM, Shridhar V, Sutphen R, Couch FJ, Sellers TA; Ovarian Cancer Association Consortium. Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 20, 1638-48 (2011)
PubMed link      E-mail link

Reference Number: 1143
Wei W, Kong B, Qu X. Alteration of HGF and TSP-1 expression in ovarian carcinoma associated with clinical features. J Obstet Gynaecol Res. 38, 57-64 (2012)
PubMed link      E-mail link

Reference Number: 1645
Kwon Y, Smith BD, Zhou Y, Kaufman MD, Godwin AK. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene 34, 144-53 (2015)
PubMed link      E-mail link

Reference Number: 1695
Mariani M, McHugh M, Petrillo M, Sieber S, He S, Andreoli M, Wu Z, Fiedler P, Scambia G, Shahabi S, Ferlini C. HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget. 5, 4855-67 (2014)
PubMed link      E-mail link

Reference Number: 1864
Nakamura M, Ono YJ, Kanemura M, Tanaka T, Hayashi M, Terai Y, Ohmichi M. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum. Gynecol Oncol. 139, 345-54 (2015)
PubMed link      E-mail link

Reference Number: 1870
Nakamura M, Ono YJ, Kanemura M, Tanaka T, Hayashi M, Terai Y, Ohmichi M. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum. Gynecol Oncol. 139, 345-54 (2015)
PubMed link      E-mail link

Pancreas/Gall Bladder

Reference Number: 109
La Rosa, S., Uccella, S., Capella, C., Erba, S. & Sessa, F. Localization of Hepatocyte Growth Factor and Its Receptor met in Endocrine Cells and Related Tumors of the Gut and Pancreas: An Immunohistochemical Study. Endocr Pathol 11, 315-329. (2000).
PubMed link      E-mail link

Reference Number: 364
Shimura H, Date K, Matsumoto K, Nakamura T, Tanaka M. Induction of invasive growth in a gallbladder cancer cell line by hepatocyte growth factor in vitro. Jpn J Cancer Res. 86, 662-9 (1995)
PubMed link      E-mail link

Reference Number: 366
Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene. 17, 3045-54 (1998)
PubMed link      E-mail link

Reference Number: 393
Murakami M, Nagai E, Mizumoto K, Saimura M, Ohuchida K, Inadome N, Matsumoto K, Nakamura T, Maemondo M, Nukiwa T, Tanaka M. Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice. Int J Cancer. 117, 160-5 (2005)
PubMed link      E-mail link

Reference Number: 415
Li H, Shimura H, Aoki Y, Date K, Matsumoto K, Nakamura T, Tanaka M. Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro. Clin Exp Metastasis. 16, 74-82 (1998)
PubMed link      E-mail link

Reference Number: 497
Matsumoto K, Date K, Shimura H, Nakamura T. Acquisition of invasive phenotype in gallbladder cancer cells via mutual interaction of stromal fibroblasts and cancer cells as mediated by hepatocyte growth factor. Jpn J Cancer Res. 87, 702-10 (1996)
PubMed link      E-mail link

Reference Number: 502
Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, Evans DB, Gallick GE, Ellis LM. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther. 5, 1676-82 (2006)
PubMed link      E-mail link

Reference Number: 597
Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K, Miyazaki K. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol. 14, 2600-7 (2007)
PubMed link      E-mail link

Reference Number: 598
Tanaka T, Shimura H, Sasaki T, Narumi K, Maemondo M, Nukiwa T, Matsumoto K, Nakamura T, Ikeda S. Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model. Cancer Gene Ther. 11, 431-40 (2004)
PubMed link      E-mail link

Reference Number: 599
Hasina R, Matsumoto K, Matsumoto-Taniura N, Kato I, Sakuda M, Nakamura T. Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line. Br J Cancer. 80, 1708-17 (1999)
PubMed link      E-mail link

Reference Number: 609
Matsushita A, Götze T, Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res. 67, 10309-16 (2007)
PubMed link      E-mail link

Reference Number: 648
Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-8 (2008)
PubMed link      E-mail link

Reference Number: 650
Kitajima Y, Ide T, Ohtsuka T, Miyazaki K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 99, 1341-7 (2008)
PubMed link      E-mail link

Reference Number: 660
Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K, Gendler SJ, Bennett EP, Hollingsworth MA. Phosphorylation of MUC1 by met modulates interaction with p53 and MMP1 expression. J Biol Chem. 2008 Jul 14. [Epub ahead of print]
PubMed link      E-mail link

Reference Number: 672
Cruz-Monserrate Z, O'Connor KL. Integrin alpha 6 beta 4 promotes migration, invasion through Tiam1 upregulation, and subsequent Rac activation. Neoplasia. 10, 408-17 (2008)
PubMed link      E-mail link

Reference Number: 718
Chan GK, Lutterbach BA, Pan BS, Kariv I, Szewczak AA. High-throughput analysis of HGF-stimulated cell scattering. J Biomol Screen. 13, 847-54 (2008) Epub 2008 Sep 23
PubMed link      E-mail link

Reference Number: 722
Justinger C, Schlüter C, Oliviera-Frick V, Kopp B, Rubie C, Schilling MK. Increased growth factor expression after hepatic and pancreatic resection. Oncol Rep. 20, 1527-31 (2008)
PubMed link      E-mail link

Reference Number: 933
Tan XG, Yang ZL. Expression of Ezrin, HGF, C-met in pancreatic cancer and non-cancerous pancreatic tissues of rats. Hepatobiliary Pancreat Dis Int. 9, 639-44 (2010)
PubMed link      E-mail link

Reference Number: 937
Argast GM, Mercado P, Mulford IJ, O'Connor M, Keane DM, Shaaban S, Epstein DM, Pachter JA, Kan JL. Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-ß enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs. 193, 114-32 (2011)
PubMed link      E-mail link

Reference Number: 1223
Yang L, Guo T, Jiang S, Yang Z. Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder. Hepatogastroenterology. 59, 1769-75 (2012)
PubMed link      E-mail link

Reference Number: 1534
Oyanagi J, Kojima N, Sato H, Higashi S, Kikuchi K, Sakai K, Matsumoto K, Miyazaki K. Inhibition of transforming growth factor-ß signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor. Exp Cell Res. 326, 267-79 (2014)
PubMed link      E-mail link

Reference Number: 1608
Sun YP, Zhang BL, Duan JW, Wu HH, Wang BQ, Yu ZP, Yang WJ, Shan YF, Zhou MT, Zhang QY. Effect of NK4 transduction in bone marrow-derived mesenchymal stem cells on biological characteristics of pancreatic cancer cells. Int J Mol Sci. 15, 3729-45 (2014)
PubMed link      E-mail link

Reference Number: 1609
Patel MB, Pothula SP, Xu Z, Lee AK, Goldstein D, Pirola RC, Apte MV, Wilson JS. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. Carcinogenesis. 35, 1891-900 (2014)
PubMed link      E-mail link

Reference Number: 1871
Carpenter BL, Chen M, Knifley T, Davis KA, Harrison SM, Stewart RL, O'Connor KL. Integrin a6ß4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF). J Biol Chem. 290, 27228-38 (2015)
PubMed link      E-mail link

Prostate

Reference Number: 119
Zhu, X. & Humphrey, P. A. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 56, 1071-4 (2000).
PubMed link      E-mail link

Reference Number: 248
Nakashiro K, Hayashi Y, Oyasu R. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncol Rep 10:1149-53 (2003).
PubMed link      E-mail link

Reference Number: 325
MacDougall CA, Vargas M, Soares CR, Holzer RG, Ide AE, Jorcyk CL, Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c. Prostate 64,139-48 (2005)
PubMed link      E-mail link

Reference Number: 326
Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24, 101-6 (2005)
PubMed link      E-mail link

Reference Number: 363
Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, Sturzebecher J, Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol. 27, 1061-70 (2005)
PubMed link      E-mail link

Reference Number: 371
Nagakawa O, Yamagishi T, Akashi T, Nagaike K, Fuse H. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer. Prostate 66, 447-52 (2006)
PubMed link      E-mail link

Reference Number: 372
Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene. 25, 2367-78 (2006)
PubMed link      E-mail link

Reference Number: 373
Wells CM, Ahmed T, Masters JR, Jones GE. Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. Cell Motil Cytoskeleton 62, 180-94 (2005)
PubMed link      E-mail link

Reference Number: 376
Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, Jiang WG. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol Histopathol. 20, 1339-49 (2005)
PubMed link      E-mail link

Reference Number: 377
Nagakawa O, Yamagishi T, Fujiuchi Y, Junicho A, Akashi T, Nagaike K, Fuse H. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. Eur Urol. 48, 686-90 (2005)
PubMed link      E-mail link

Reference Number: 378
Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol. 167, 255-66 (2005)
PubMed link      E-mail link

Reference Number: 379
Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 390, 125-36 (2005)
PubMed link      E-mail link

Reference Number: 380
Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 579, 1945-50 (2005)
PubMed link      E-mail link

Reference Number: 381
Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S, Pestell RG, Goldberg ID, Rosen EM. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 24, 1749-66 (2005)
PubMed link      E-mail link

Reference Number: 385
Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 66, 794-802 (2006)
PubMed link      E-mail link

Reference Number: 386
Hashem M, Essam T. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer. J Egypt Natl Canc Inst. 17, 114-20 (2005)
PubMed link      E-mail link

Reference Number: 475
Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer. 4, 269-74 (2006)
PubMed link      E-mail link

Reference Number: 587
Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Namba Y, Kishikawa H, Takahara S, Ichikawa Y. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels. Prostate Cancer Prostatic Dis. 11, 258-63 (2008)
PubMed link      E-mail link

Reference Number: 588
Sanders AJ, Parr C, Mason MD, Jiang WG. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med. 20, 613-9 (2007)
PubMed link      E-mail link

Reference Number: 631
Shukla CJ, Pennington CJ, Riddick AC, Sethia KK, Ball RY, Edwards DR. Laser-capture microdissection in prostate cancer research: establishment and validation of a powerful tool for the assessment of tumour-stroma interactions. BJU Int. 101, 765-74 (2008)
PubMed link      E-mail link

Reference Number: 654
Ye L, Lewis-Russell JM, Sanders AJ, Kynaston H, Jiang WG. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. Urol Oncol. 26, 190-7 (2008)
PubMed link      E-mail link

Reference Number: 688
Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res. 14, 7385-90 (2008)
PubMed link      E-mail link

Reference Number: 720
Yasuda K, Nagakawa O, Akashi T, Fujiuchi Y, Koizumi K, Komiya A, Saiki I, Fuse H. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate 69, 346-51 (2009)
PubMed link      E-mail link

Reference Number: 727
Wells CM, Whale AD, Parsons M, Masters JR, Jones GE. PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J Cell Sci. 123(Pt 10), 1663-73 (2010)
PubMed link      E-mail link

Reference Number: 927
Wang Y, Yue D, Li K, Liu YL, Ren CS, Wang P. The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells. Asian J Androl. 12, 841-52 (2010)
PubMed link      E-mail link

Reference Number: 930
Ahmed T, Shea K, Masters JR, Jones GE, Wells CM. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal. 20, 1320-8 (2008)
PubMed link      E-mail link

Reference Number: 941
Bright MD, Garner AP, Ridley AJ. PAK1 and PAK2 have different roles in HGF-induced morphological responses. Cell Signal. 21, 1738-47 (2009)
PubMed link      E-mail link

Reference Number: 1284
Nishida S, Hirohashi Y, Torigoe T, Inoue R, Kitamura H, Tanaka T, Takahashi A, Asanuma H, Masumori N, Tsukamoto T, Sato N. Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor. Cancer Sci. 104, 431-6 (2013)
PubMed link      E-mail link

Reference Number: 1622
Martin TA, Mason MD, Jiang WG. HGF and the regulation of tight junctions in human prostate cancer cells. Oncol Rep. 32, 213-24 (2014)
PubMed link      E-mail link

Reference Number: 1850
Cecchi F, Lih CJ, Lee YH, Walsh W, Rabe DC, Williams PM, Bottaro DP. Expression array analysis of the hepatocyte growth factor invasive program. Clin Exp Metastasis. 32, 659-76 (2015)
PubMed link      E-mail link

Rhabdomyosarcoma

Reference Number: 510
Rees H, Williamson D, Papanastasiou A, Jina N, Nabarro S, Shipley J, Anderson J. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors. 24, 197-208 (2006)
PubMed link      E-mail link

Reference Number: 531
Williamson D, Selfe J, Gordon T, Lu YJ, Pritchard-Jones K, Murai K, Jones P, Workman P, Shipley J. Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res. 67, 57-65 (2007)
PubMed link      E-mail link

Synovial Sarcoma

Reference Number: 146
Kuhnen, C., Tolnay, E., Steinau, H. U., Voss, B. & Muller, K. M. Expression of c-Met receptor and hepatocyte growth factor/scatter factor in synovial sarcoma and epithelioid sarcoma. Virchows Arch 432, 337-42 (1998).
PubMed link      E-mail link

Reference Number: 147
Motoi, T. et al. Coexpression of hepatocyte growth factor and c-Met proto-oncogene product in synovial sarcoma. Pathol Int 48, 769-75 (1998).
PubMed link      E-mail link

Reference Number: 148
Oda, Y. et al. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol 31, 185-92 (2000).
PubMed link      E-mail link

Thyroid

Reference Number: 127
Papotti, M. et al. Expression of hepatocyte growth factor O(HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocrine Pathology 11, 19-30 (2000).
PubMed link      E-mail link

Reference Number: 250
Trovato M, Grosso M, Vitarelli E, Ruggeri RM, Alesci S, Trimarchi F, Barresi G, Benvenga S. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas. Histol Histopathol 18:393-9 (2003).
PubMed link      E-mail link

Reference Number: 329
Scarpino S, Di Napoli A, Taraboletti G, Cancrini A, Ruco LP. Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells. J Pathol. 205, 50-6 (2005)
PubMed link      E-mail link

Reference Number: 559
Ghoneim C, Soula-Rothhut M, Blanchevoye C, Martiny L, Antonicelli F, Rothhut B. Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. J Biol Chem. 282, 15490-7 (2007)
PubMed link      E-mail link

Reference Number: 1178
Ruggeri RM, Vitarelli E, Barresi G, Trimarchi F, Benvenga S, Trovato M. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization. Histol Histopathol. 27, 113-21 (2012)
PubMed link      E-mail link

Reference Number: 1616
Koo BS, Kim JM, Seo ST, Yoon YH, Kwon KR, Kim SH, Kwon HW, Bae WJ, Lim YC. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol. 21, 2310-7 (2014)
PubMed link      E-mail link

Wilms' Tumor

Reference Number: 216
Alami, J., Williams, B. R. & Yeger, H. Expression and localization of HGF and met in Wilms' tumours. J Pathol 196, 76-84. (2002).
PubMed link      E-mail link

Reference Number: 274
Higinbotham KG, Karavanova ID, Diwan BA, Perantoni AO. Deficient expression of mRNA for the putative inductive factor bone morphogenetic protein-7 in chemically initiated rat nephroblastomas. Mol Carcinog. 23, 53-61 (1998)
PubMed link      E-mail link

Reference Number: 732
Vuononvirta R, Sebire NJ, Messahel B, Perusinghe N, Reis-Filho JS, Pritchard-Jones K, Vujanic GM, Jones C. Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development. Clin Cancer Res. 15, 2723-30 (2009)
PubMed link      E-mail link